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ABSTRACT
The population of patients suffering from sleep-disordered breathing (SDB), especially
obstructive sleep apnoea (OSA) is rising. OSA is often treated with continuous positive
airway pressure (CPAP), but data on the long-term effects are scarce. SDB is an
umbrella term for different types of SDB, that may have a similar nocturnal breathing
disorder, while the underlying mechanisms are different as well as the risks that come
from having an untreated condition. In the future, treatment will be more
individualised, and CPAP therapy might not be the first or the best choice for all
patients. Thus, more information on the long-term effects of CPAP therapy is needed.
In order to study the lifestyle, weight changes, and leptin and Insulin-like Growth
Factor 1 (IGF-1) concentrations during long-term CPAP therapy, patients who were 
referred to the Pulmonary ward of the Turku University Hospital for suspected sleep
apnoea were enrolled in the study (n=223). Patients were given an array of
questionnaires on sleep duration and quality, sleepiness, depressive symptoms and
anxiety, cravings for different food categories, and exercise habits. All had a 
cardiorespiratory polygraphy (PG), and their blood was drawn following an
overnight fast. After three years of follow-up, the patients were divided into CPAP
users (n= 76) and non-users (n= 73), and all measurements except the sleep study,
were repeated. The use of medication for comorbidities was evaluated for women
referred to Paimio Hospital between 1994-1998 for suspected sleep apnoea (n= 601).
The medication data were derived from the National Reimbursement registration
three years before, and three years after CPAP initiation or the sleep study. Women
were divided into CPAP users (n=66) and the control group (n= 122). The SDB type
was also considered in the analysis.
In our study, long-term CPAP therapy alleviated SDB symptoms, depressive 
symptoms, and anxiety efficiently. However, it did not influence lifestyle or exercise
habits, and the patients did not lose weight. Increase in weight was associated with
a good adherence to CPAP. In women, leptin concentrations increased, especially if
they used CPAP. IGF-1 concentrations did not change. Medication use for
comorbidities continued to increase regardless of CPAP therapy and CPAP users
already had more comorbidities before the CPAP therapy initiation. However, the
increase in medicine use did not differ between the CPAP users and non-users. The
type of SDB also did not influence medicine use.
In conclusion, patients with SDB should have sufficient life-style counselling as
well as CPAP therapy. CPAP therapy does not automatically decrease medication
use and thus the cost. Earlier diagnosis and treatment of SDB before end-organ 
manifestations might instead reduce health care costs. The different profile for
female SDB patients should also be noted and remembered.
KEYWORDS: Sleep disordered breathing, CPAP, OSA, lifestyle, leptin, medicine
use, comorbidities
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MIIA ARO: Pitkäaikaisen CPAP-hoidon vaikutukset unenaikaista 
hengityshäiriötä sairastavilla.
Turun kliininen tohtoriohjelma
Marraskuu 2020
TIIVISTELMÄ
Unenaikaista hengityshäiriötä sairastavien määrä on kasvussa, ja erityisesti
obstruktiivista uniapneaa sairastavia potilaita on vuosi vuodelta enemmän.
Uniapneaa hoidetaan usein ylipainehengityslaitteella (continuous positive airway
pressure, CPAP). Unenaikainen hengityshäiriö on sateenvarjotermi, jonka alta
löytyy eri alatyyppejä, joita yhdistävät unenaikaiset hengityskatkokset, mutta niiden 
syntymekanismit ja riskiprofiili vaihtelevat. Tulevaisuudessa siirryttäneenkin
yksilöllisempään hoitoon, jolloin CPAP ei ole ensisijainen hoitomuoto kaikille.
Tämän vuoksi lisätieto CPAP-hoidon pitkäaikaisvaikutuksista on erityisen tärkeää.
Tutkiaksemme elintapoja, painon muutosta sekä leptiinin ja insuliinikaltaisen
kasvutekijä 1:n (IGF-1) pitoisuuksia pitkäaikaisen CPAP-hoidon aikana, Turun 
yliopistollisen keskussairaalan keuhkoklinikalle uniapneaepäilyn vuoksi lähetetyille
223 potilaalle annettiin kyselylomakkeita, joissa kysyttiin unen pituudesta ja laadusta,
uneliaisuudesta, masennus- tai ahdistusoireista, erilaisten ruokien mieliteoista sekä
liikuntatottumuksista. Lisäksi heille tehtiin yöpolygrafia ja otettiin paastoverinäyte.
Potilaat jaettiin kolmen vuoden seuranta-ajan jälkeen CPAP-käyttäjiin (n=76) ja ei-
käyttäjiin (n=73) ja heille tehtiin yöpolygrafiaa lukuun ottamatta samat tutkimukset. 
Lääkkeiden käyttöä tutkittiin Paimion sairaalaan v. 1994-1998 uniapneaepäilyn vuoksi
unipatjatutkimukseen tulleiden naisten avulla (n=601). Lääkekäyttötiedot Kelalta
pyydettiin kolme vuotta ennen ja kolme vuotta laitehoidon aloituksen tai rekiste-
röintipäivän jälkeen. Naiset jaettiin joko CPAP-käyttäjiin (n=66) tai verrokkeihin
(n=122). Myös unenaikaisen hengityshäiriön tyyppi otettiin huomioon.
Tutkimuksessamme pitkäaikainen CPAP-hoito lievitti tehokkaasti unenaikaisen
hengityshäiriön oireita sekä masennus- ja ahdistuneisuusoireita. Hoidolla ei ollut 
vaikutusta potilaiden elintapoihin, eivätkä potilaat laihtuneet. Painon nousu oli 
yhteydessä tehokkaaseen CPAP-laitteen käyttöön. Naisilla leptiinipitoisuudet 
nousivat hoidon aikana, erityisesti jos he käyttivät CPAP-laitetta. Insuliininkaltaisen
kasvutekijä 1:n-pitoisuudet eivät muuttuneet. Liitännäissairauksien lääkekäyttö
jatkoi nousuaan CPAP-hoidosta huolimatta, ja CPAP:n käyttäjillä oli jo alku-
vaiheessa enemmän sairauksia kuin verrokeilla. Lääkekäytön lisääntyminen ei
eronnut CPAP-hoitoa käyttävillä ja ei-käyttäjillä. Unenaikaisen hengityshäiriön
tyypillä ei ollut vaikutusta lääkekäyttöön.
Tulostemme valossa ehdotamme, että uniapneaa sairastaville tulisi CPAP-
hoidon lisäksi tarjota tehokasta elintapavalmennusta. CPAP-hoito ei automaattisesti
vähennä lääkekulutusta. Varhaisempi uniapnean diagnosointi ja hoito saattaisi estää
liitännäissairauksien kehittymistä ja säästää terveydenhuollon kuluja. Lisäksi naisten
erilainen taudinkuva tulisi muistaa.
AVAINSANAT: CPAP, unenaikainen hengityshäiriö, obstruktiivinen uniapnea,
elintavat, leptiini, lääkkeiden käyttö, liitännäissairaudet
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ABBREVIATIONS 
ACS Acute coronary syndrome
AF Atrial fibrillation
AHI Apnoea-hypopnea index
BBB Blood-brain barrier
BMI Body mass index
CB Carotid body
CGRP Calcitonin gene-related peptide
CNS Central nervous system
COMISA Comorbid insomnia and OSA
COPD Chronic obstructive pulmonary disease
CPAP Continuous positive airway pressure
CSA Central sleep apnoea
CSN Carotid sinus nerve
CV(D) Cardiovascular (disease)
DDD Defined daily dose
DEPS Depressive symptom scale
ECG Electrocardiography
EDS Excessive daytime sleepiness
EEG Electroencephalography
EMG Electromyography
EOG Electrooculography
ESS Epworth Sleepiness Scale
GHQ-12 General Health Questionnaire
HADS Hospital Anxiety and Depression Scale
HNS Hypoglossal nerve stimulation
HVR Hypoxic ventilatory response
IGF-1 Insulin-like growth factor-1
IRR Increased respiratory resistance
MAD Mandibular advancement device
MMA Maxillomandibular Advancement
MSLT Multiple Sleep Latency Test
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MWT Maintenance of Wakefulness Test
NREM Non-REM sleep stage
NTS Nucleus of the solitary tract
ODI Oxygen desaturation index
OSA(S) Obstructive sleep apnoea (syndrome)
Pcrit Critical closing pressure of the airway
PG Cardiorespiratory polygraphy
PLMS Periodic leg movement syndrome
POSA Positional obstructive sleep apnoea
PSG Polysomnography
PSQI Pittsburgh Sleep Quality Index
PtcCO2 Transcutaneous carbon dioxide
QoL Quality of life
REM Rapid Eye Movement
RERA Respiratory effort related arousals
RIP Respiratory inductive plethysmography
SaO2 Arterial oxyhaemoglobin saturation
SCSB Static-charge-sensitive bed
SDB Sleep-disordered breathing
STAI State-trait anxiety inventory 
TIA Transient ischemic attack
TIB Time in bed
TSH Thyroid stimulating hormone
UAO Upper airway obstruction
UPPP Uvulopalatopharyngoplasty
VAS Visual analogue scale
WHR Waist hip ratio
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1 INTRODUCTION
The prevalence of sleep-disordered breathing (SDB) is rising, largely due to the
increase in obesity (Heinzer et al. 2015). Continuous positive airway pressure
(CPAP) therapy is the gold standard for treating patients who have moderate-to-
severe obstructive sleep apnoea (OSA) (Sullivan et al. 1981). As CPAP therapy has
become more common, the positive and negative effects of long-term therapy have
drawn additional attention. The rising population who have OSA is creating
increased healthcare costs including increased medication cost, more sick leave, and
more hospitalisations. The cost-effectiveness of CPAP therapy needs more research, 
especially regarding long-term treatment (Jennum & Kjellberg 2011). At the same
time, the knowledge of SDB has increased, and thus, currently we know that SDB is
merely an umbrella term for different conditions with different risks and 
pathophysiology, sharing the characteristic of disturbed nocturnal breathing
(Zinchuk & Yaggi 2019). Therefore, in the future, not all patients will be treated with
CPAP and gaining more data on who benefits the most, is highly encouraged.
The most common risk factor for SDB is obesity (Young et al. 1993). Thus, it
has been assumed that initiating CPAP therapy will alleviate SDB symptoms such
as sleepiness and poor sleep quality, thereby leading to more daytime activity, and
healthier food choices resulting in weight loss. The data on these long-term effects
have been controversial, and the studies have consisted mainly of men with OSA.
The consensus in short-term CPAP use is that it may or may not promote weight gain
(Drager et al. 2015). These changes in lifestyle and food consumption, however,
have not been thoroughly studied, even if they are viewed as important factors in
achieving weight change.
The effect of gender on SDB has been recognised in the shift of the millennium
(Bixler et al. 2001). Clinical presentation of SDB differs between genders, but the
data on the effects of CPAP have been collected primarily on male cohorts. The data
on female SDB are, however, delightfully increasing and in the near future will likely
result in a more detailed evaluation of gender differences. Currently we know that
female SDB is under-diagnosed and under-treated, and the symptoms and risks for
SDB also appear to differ from those for men (Bonsignore et al. 2019b). 
12
 
  
         
     
     
    
 
   
     
     
 
 
 
Introduction
This thesis thus evaluated multiple factors to find clear predictors of weight gain
for patients receiving long-term CPAP therapy. Our goal was to investigate whether
CPAP therapy alleviates SDB symptoms and leads to healthier lifestyle. In addition, 
the differences between the genders were of clear interest. Leptin and Insulin-like
Growth Factor 1 (IGF-1) could perhaps play an important role in weight reduction,
and thus they were controlled, separately for both genders. Finally, the cost-
effectiveness of CPAP therapy in women with both overall medication and different
medication subgroups were evaluated. SDB type was also included in these analyses.
13
 
    
     
   
  
   
  
  
    
       
  
    
 
       
        
   
   
   
     
     
   
   
   
       
   
     
       
   
   
  
 
    
2 REVIEW OF THE LITERATURE
Sleep-disordered breathing (SDB) is a medical condition, where pharyngeal space is
narrowed or obstructed during sleep, leading to repetitive pauses in breathing, sleep
fragmentation, and oxygen desaturation events (Malhotra & White 2002). The
variations in SDB range from increased upper-airway resistance to obstructive sleep
apnoea syndrome (OSAS), where in addition to complete collapse (apnoea) and 
partial collapse (hypopnoea) of airways, patients suffer from a broad spectrum of
daytime symptoms (Malhotra & White 2002). SDB is an umbrella term, and as such,
it includes obstructive sleep apnoea (OSA), central sleep apnoea (CSA), sleep-
related hypoventilation disorders, and sleep-related hypoxemia disorder (Sateia
2014), with OSA being the most common.
2.1 Epidemiology 
In Western countries, the prevalence of SDB is currently rising. In the 1990’s the
Sleep Heart Health Study estimated that 24 % of men and 9 % of women suffered
from OSA in middle age, and 4 % of men and 2 % of women had OSAS (Young et
al. 1993). Peppard et al. updated prevalence two decades later in the Wisconsin Sleep
Study Cohort, suggesting that 27 % of men and 12 % of women age 30-70 suffered
from moderate to severe OSA (Peppard et al. 2013). Along with improvement in and 
an increased sensitivity of technology, the diagnostic criteria for OSA changed in
2012, leading to even more increased SDB prevalence (Berry et al. 2012).
One of the first studies that commenced after the changed criteria, was the
HypnoLaus study, where the prevalence of moderate to severe OSA was as high as
49.7 % in men and 23.4 % in women, aged 40-85 years (Heinzer et al. 2015). The
changed criteria, and this unforeseen increase in the number of OSA patients, craved
further and more profound prevalence investigation. In a recent review, SDB
prevalence ranges from 24 to 83.8 % in men and from 9 to 76.6 % in women, and
moderate-to-severe SDB from 7.2 to 67.2 % in men and 4 to 50.9 % in women
(Matsumoto & Chin 2019).
The results before and after the change in diagnostic criteria are challenging to
compare, hence the actual increase remains unclear. Moreover, the studies are 
difficult to compare due to varying patient selection and possible bias regarding
14
 
  
    
   
  
    
     
   
      
      
 
    
   
   
     
     
  
  
 
   
  
  
   
       
   
    
  
 
   
 
   
    
    
     
   
      
   
     
2.2.1 
Review of the literature
certain medical comorbidities, that are of particular and related interest. The
extremely high prevalence estimates also raise the question of whether part of the
OSA is just a physiologic or compensatory phenomenon that does not require
treatment (Dempsey et al. 2010). The high prevalence rates call for more research
on who should be treated and how to be treated, and how OSA can be prevented.
In terms of ethnicity, the African American population and the Hispanic
population develops more OSA than the Caucasian population does (Foldvary-
Schaefer & Waters 2017). Elderly have more OSA than younger controls, and in the
Osteoporotic Fractures in Men Sleep Study, moderate-to-severe OSA was found in
26.5 % of men over 65, and that prevalence increased with age, leading to 30.1 % of
patients over 80 years in age being affected (Mehra et al. 2007). It has also been
suggested that with age, the prevalence of REM (rapid eye movement) related SDB
increases, and indeed, in one study, the prevalence was 42.8 % in men over 65 (Khan
et al. 2013). Increased risk of OSA with age could also be associated with a reduction
in slow wave sleep, which is thought to protect from SDB and airway collapse, 
combined with the natural age-related tissue loosening. (Van Cauter et al. 2000). 
Older men are also less symptomatic and report less daytime sleepiness and fatigue 
(Mehra et al. 2007). Premenopausal women have less SDB than men, but after
menopause, prevalence increases significantly, and approaches that seen in men
(Anttalainen et al. 2006; Bixler et al. 2001).
2.2 Pathophysiology
Anatomical factors
Anatomical features play an important role in the development of SDB. Nocturnal
pauses in breathing are a result of the anatomical collapse of pharyngeal structures,
and alterations in the function of the upper airway muscles (Patil et al. 2007). The
upper airway is composed of soft tissue between the larynx and the hard palate. The
soft palate has five pairs of muscles (Table 1), and their function is to maintain
patency during breathing. They are the most important determinants of proper
pharyngeal space.
Most patients who are suffering from SDB are obese; however, over 30 % of
SDB patients are lean (Malhotra & White 2002). Obesity increases the incidence of
SDB, and any increase in weight by 10 % increases the incidence of SDB six-fold, 
and AHI by 30 % (Peppard et al. 2000). Airway size is affected by obesity via several
mechanisms, but the accumulation of fat narrows the pharyngeal tube mechanically
and offsets the dilatory function in the neck muscles, resulting in an increased neck
circumference (Davies & Stradling 1990). Tongue fat and tongue weight correlate
to the degree of obesity (Nashi et al. 2007), and patients with OSA are shown to have
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increased retroglossal fat deposition compared to controls, even after adjustment for 
gender, age, race, and BMI. In addition, tongue fat volume correlates with AHI and
BMI (Kim et al. 2014).
Upper airway muscle activation is more strongly related to airway collapsibility
than it is to body mass index (BMI), suggesting that obesity is merely one factor that 
can cause the narrowing of the pharyngeal space (Pierce et al. 2007). Other 
craniofacial features can include congenital anomalies of the upper airway, such as 
narrow airways or maxilla, and the size and position of the cranial bones, for example
a reduced length of the mandibular body, a low hyoid bone, and retro positioning of 
the jaw (Pierce et al. 2007). In addition, traumatic incidents affecting the upper
airways or the palate and micrognathia can narrow the upper respiratory lumen via
incorrect placement of mandibula (Watanabe et al. 2002). Further still, increased
upper airway length is associated with airway collapse (Eckert 2018). 
Table 1. Muscles of pharynx and their function.
Muscle Function
Genioglossus (left and right) Protrusion of the tongue and deviation towards 
the opposite side. Together depress the center
of the tongue at its back
Tensor veli palatini Tightening of the soft palate and opening 
auditory tube
Levator veli palatini Elevation of soft palate and opening of auditory 
tube 
Palatoglossus Elevation of tongue
Palatopharyngeus Pulling the laryngeal and pharyngeal walls 
upwards during swallowing
Musculus uvulae Shortening and raising the uvula
Pharyngeal critical closing pressure (Pcrit) is the gold standard for measuring upper
airway collapsibility. It defines the minimal intraluminal airway pressure that is 
necessary to keep the airway open and higher Pcrit values indicate greater
collapsibility (Carberry et al. 2016). Pcrit is measured with the help of CPAP, in
order to minimise pharyngeal muscle activity. The holding pressure is rapidly 
reduced to varying levels to induce upper airway collapse and airflow limitation. The
value is the estimated pressure at which the upper airway collapses and airflow 
ceases (Smith et al. 1988; Wellman et al. 2011).
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Control of breathing
The physiology of breathing is complex, and anatomical factors form only part of
the intricate cascade that leads to the formation of SDB as seen in Figure 1 (Figure
drawn based on data in the article of Wellman et al. 2011). Recently, it has been
discovered that the physiological mechanisms underlying SDB vary between
patients, and we have moved toward phenotypic traits, or treatable traits, dependent
of the underlying problem. Clustering patients is still under investigation, and mostly
if not directly applicable to clinical practice as yet, but the future of treating SDB is
heading toward personalised approach, and the focus of diagnosis and treatment is
moving beyond apnoea-hypopnoea index (AHI) toward more broader evaluation
(Zinchuk & Yaggi 2019).
There are several compensatory mechanisms in our body that are involved in 
hypoxia. Hypoxic ventilatory response (HVR) is complex, involving peripheral
sensing of hypoxia, mainly in the carotid bodies (CB) located in the carotid artery
bifurcation. Information is conducted via the carotid sinus nerve (CSN) to the
nucleus of the solitary tract (NTS) and then to the brainstem. Abnormal HVR plays
an important role in the pathogenesis of SDB, as HVR increases due to intermittent 
hypoxia in SDB; however, the mechanisms are not yet fully understood (Teppema
& Dahan 2010).
Pauses in breathing can be the result of different traits. First, anatomical features
and the collapsibility of airways can be the main factors causing the apnoeas (Isono 
et al. 1997; Remmers et al. 1978). Second, pauses can be caused by a hypersensitive
ventilatory control system, often referred to as a system with a high loop gain. Loop
gain is the ability to compensate for the disturbances in breathing with an increase
in ventilatory drive. The higher the ratio between these factors, the higher will be the
loop gain as presented in Figure 2 (Wellman et al. 2011; Deacon & Catcheside 2015).
Third, upper airway muscles, especially the genioglossus muscle, can have poor
ability to respond to an increased ventilatory drive, due to the repetitive pauses in
breathing. This circumstance results in decreased Pcrit (Loewen et al. 2011). Finally, 
a low respiratory arousal threshold can cause a patient to arouse from sleep for very
small increases in respiratory drive (Berry & Gleeson 1997). In one study, it was
estimated, that 56 % of OSA patients had a significant anatomic factor influencing
their condition, 36 % had high loop gain, 36 % had low a genioglossus response to
increased ventilatory drive, and 37 % had low a arousal threshold (Eckert et al.
2013).
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Figure 1. Control of breathing. PaO2 represents the partial pressure of oxygen in arterial blood 
and PaCO2 represents the partial pressure of carbon dioxide in arterial blood.
Figure 2. Loop gain is a disturbance in ventilation divided by ventilatory response. Modified from
Wellman et al 2011.
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Comorbidities in SDB
From the early days of OSAS, it was discovered that patients have a higher risk of 
cardiovascular comorbidities (Wolk et al. 2003), but the large presence of
confounders, especially obesity, have complicated research. In recent years, the true
burden and risks of various comorbidities in OSA have been discovered, leading to
ever growing research and a vast pool of data, which are impossible to go through in
detail briefly (Bonsignore et al. 2019a). In the face of the mounting data, a score for
the risk of comorbidities has been suggested. The researchers have identified 10
comorbidities that increase OSAS patient morbidity, and after adjusting for the risk
associated with each disease state, and the number of comorbidities, a score can be
calculated. This process may be a positive step toward offering more effective
treatment, when the focus can be turned toward the most detrimental comorbidities
(Chiang et al. 2017). 
The most dangerous comorbidities are considered to be cardiovascular diseases
(CVD) such as systemic hypertension, coronary artery disease, arrhythmias, and
ischemic stroke and metabolic disorders, the most important being diabetes mellitus;
and respiratory diseases including chronic obstructive pulmonary disease (COPD) 
and asthma. Many other disorders have also been identified, including anxiety, 
insomnia, depression, and gastrointestinal diseases (Bonsignore et al. 2019a). 
Psychiatric disorders are discussed later in the symptoms section.
2.2.3.1 Cardiovascular diseases (CVD)
OSA may increase cardiovascular risk through multiple mechanisms, including high 
sympathetic nervous activity, oxidative stress, systemic hypertension, intermittent 
hypoxia, inflammation, and endothelial cell dysfunction (Lévy et al. 2015).
Repetitive pauses in breathing result in increased respiratory effort, which in turn 
leads to increased intrathoracic pressure. Due to this action, the filling mechanisms
of the left side of the heart change, resulting in impaired cardiac functioning,
inducing vasoconstriction, and eventually leading to atrial and aortic enlargement. 
Moreover, hypoxemia, hypercapnia, and arousal afflict the sympathetic nervous
system overdrive and the autonomic regulation changes in blood pressure (Figure 3)
(May et al. 2017).
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Figure 3. The mechanisms influencing on cardiovascular morbidity in SDB.
Patients with CVD have a high prevalence of SDB as seen in Table 2 (Rundo, 2019).
Table 2. The prevalence of obstructive sleep apnoea (OSA) in patients with cardiovascular
disease (Rundo et al 2019).
Disease Mild OSA (%) Moderate-to-severe OSA (%)
Hypertension
Heart failure
Arrhythmias
Stroke
Coronary heart disease
83
55
50
75
65
30
12
20
57
38
The most common, and most studied cardiovascular comorbidity is hypertension 
(Bonsignore et al. 2019a). There is also a relationship between the severity of OSAS
and hypertension (Xia et al. 2018). Resistant hypertension is common among OSAS
patients despite taking three antihypertensive medicines (Bonsignore et al. 2019a). 
Hypertension can occur during the night, daytime, or both. Therefore, 24-hour
measurement of blood pressure is advised on OSAS patients (Parati et al. 2013). 
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Review of the literature
Other significant comorbidities include arteriosclerosis and cardiac arrhythmias
(Bonsignore et al. 2019a). 
It has been estimated that 25 % of patients with acute coronary syndrome (ACS)
also have severe OSA (Huang et al. 2017). When atrial fibrillation (AF) is 
considered, studies have shown that SDB doubles the risk. In patients with both OSA
and heart failure, the risk of AF is two to four times higher than for those without
either condition (May et al. 2017). In addition, patients with peripheral arterial
disease have surprisingly high prevalence of OSA (Utriainen et al. 2013) and they 
have poorer prognosis after revascularisation (Utriainen et al. 2014). SDB is
common in patients with heart failure, but they generally do not have EDS. However,
large cohort studies in the United States have indicated that SDB with heart failure
is associated with more hospitalisations, increased medical costs, and excess
mortality (Javaheri et al. 2020). Moreover, SDB is common in both, stroke patients
and in ischemic stroke patients and SDB is also an independent risk factor for a 
stroke, even when other risk factors such as hypertension, diabetes mellitus,
hyperlipidaemia, and AF are controlled. Therefore, all patients hospitalised for
stroke or transient ischemic attack (TIA) should be screened for SDB (Jehan et al.
2018).
2.2.3.2 Metabolic diseases
The majority of patients with SDB, especially OSAS, additionally have obesity
(Malhotra & White 2002). Obesity is known to interfere with energy balance and
also affect adipose tissue inflammation (Schenk et al. 2008). In addition, OSA and
obesity have a bilateral and complex relationship via multiple mechanisms, making 
it merely impossible to consider these two conditions separately (Bonsignore et al.
2012). On the other hand, OSA causes sleep fragmentation and hypoxia that can
influence glucose metabolism, making OSA an independent risk factor for diabetes
as well (Reutrakul & Mokhlesi 2017). In diabetic patients with OSA, the prevalence
of neuropathy, nephropathy, retinopathy and peripheral arterial disease increase
(Bonsignore et al. 2019a), making it essential to take OSA into consideration when
treating diabetic patients.
2.2.3.3 Respiratory diseases
COPD is known to coincide with OSA (Flenley 1985; Owens et al. 2017) and asthma
and OSA is also thought to have a causal link (Kong et al. 2017). The prevalence of
a OSA-COPD overlap syndrome has been reported to range from 1 to 3.6 % in the
general population, 8-56 % in OSA patients, and 3-66 % in COPD patients (Shawon
et al. 2017). SDB in COPD patients in mainly seen in REM phase of sleep, due to
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reduced intercostal muscle activity and chest wall mobility (Johnson & Remmers
1984). Moreover, patients with overlap syndrome have been reported to have a
poorer health related quality of life (QoL), in part related to sleep disruption and
worse nocturnal oxygenation. Overlap syndrome is considered to cause rising health
care costs, as SDB has been shown to increase the rate of COPD exacerbation,
hospitalisation, and even mortality when compared to COPD-only patients (Shawon
et al. 2017). In addition, overlap syndrome has been associated with pulmonary
hypertension and respiratory failure (Singh et al. 2018).
The results of the link between asthma and OSA severity are controversial
(Julien et al. 2009; Tveit et al. 2018). It has been suggested, that especially women
with obesity have a higher prevalence of asthma (Bonsignore et al. 2018). In patients
who have difficult-to-treat asthma, mild to moderate OSA was found in 49 % (Taillé
et al. 2016). Patients who have severe asthma, can experience similar symptoms as
those for SDB, such as poor sleep quality and daytime sleepiness, making differential
diagnosis challenging (Julien et al. 2009). In part, the underlying inflammatory
mechanism can be similar in both conditions, as it has been shown that upper airways
are smaller in size in both SDB and asthma patients (Dultra et al. 2017). In patients 
with both asthma and SDB, the main type of respiratory event has proven to be
hypopnoea (Julien et al. 2009).
2.3 Symptoms of SDB
Sleepiness
The most detrimental symptom of SDB is excessive daytime sleepiness (EDS)
(Ramar & Guilleminault 2006; Stepanski et al. 1984). It is a highly subjective
symptom, but there are a range of questionnaires that have been developed for
evaluating EDS with the Epworth Sleepiness Scale (ESS) being the most common
(Johns 1991). In addition, EDS is widely present in the general population, the
estimate being 12 % (Hyon & Young 2005) and there are evaluations that indicate
EDS may be more strongly associated with depression and metabolic factors than
with SDB, and that EDS is more common in people under 30 years or over 70 years
in age (Bixler et al. 2005). 
There are no standard description for EDS, but it is often described as the
inability to stay awake and alert during the day when the circadian sleep drive
promotes alertness (Arand et al. 2005). Sleepiness is associated with an increased
risk for traffic accidents (Sanna 2012; Tregear et al. 2009), increased medical
expenses (Guest et al. 2008; Jennum & Kjellberg 2011), and more sick leave 
(Jennum & Kjellberg, 2011).
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EDS among OSA patients is estimated to vary from 19 to 87.2 % (Garbarino et al.
2018b). However, ESS poorly correlates with objective tests of vigilance such as
multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT),
their sensitivity ranging from poor-to-moderate (Johns 2000). Moreover, EDS is not a 
symptom specific to SDB, but rather the wide range of other comorbidities that often
occur in the same patients (Saaresranta et al. 2016). However, the recent clustering
analysis of the phenotypes of SDB, the traditional sleepy-type OSA patient was not
the most common phenotype. Surprisingly, the non-sleepy clusters, had a higher risk
for CVD than did patients with EDS (Anttalainen et al. 2019; Ye et al. 2014).
2.3.2 Depression
The estimations of the prevalence of depressive symptoms among patients with SDB
do vary in studies and range from 7 % to 63 % (Saunamäki & Jehkonen 2007). In 
addition, people with major depressive disorders are five times more likely to have 
SDB than are the controls (Ohayon 2003). Depressive symptoms are also present
especially among women with SDB. In one study, women had more depressive
symptoms than men, regardless of their SDB severity. The more severe the SDB
was, the more depressive symptoms they had (Pillar & Lavie 1998).
Surprisingly, women who only snored, had more depressive symptoms than the
women with mild OSA, in all age groups, perhaps referring to prolonged upper
airway resistance (Pillar & Lavie 1998). Symptoms of true depression overlap with
SDB especially in women, and can be mistaken as mental illness (Pillar & Lavie
1998). Depressive symptoms can be evaluated using numerous questionnaires;
DEPS (Salokangas et al. 1995) widely used in Finland, and Beck Depression
Inventory (BDI)(Beck et al. 1996) used worldwide. Earlier studies on the correlation
between the severity of SDB and depressive symptoms have been contradictory
(Muñoz et al. 2000; Sánchez et al. 2001). However, a recent study suggested, that
mild SDB correlated with more depressive symptoms, and additionally, depressive 
symptoms were associated with EDS (Lee et al. 2019). 
2.3.3 Anxiety
Anxiety related to SDB is not as thoroughly investigated as are depressive
symptoms. Currently it is estimated, that approximately half of the patients with SDB
also suffer from anxiety (Lee et al. 2019; Rezaeitalab et al. 2014), and tend to have
more anxiety than the general population (Rezaeitalab et al. 2014). However, it has
been suggested that anxiety is more often present in patients with less severe SDB
(Lee et al. 2019). Moreover, if female patients have both insomnia and SDB, they
are also more likely to have anxiety (Foster et al. 2017).
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2.3.4 Nocturnal symptoms
The most characteristic symptom of OSA is snoring, which occur in 70 -95 % of
SDB patients (Guilleminault & Bassiri 2005) and 75 % of patients report pauses in
breathing during sleep (Guilleminault et al. 1977; Guilleminault & Bassiri 2005). 
Other nocturnal symptoms include nocturia in 28 % of patients (Guilleminault &
Bassiri 2005; Miyazaki et al. 2015), waking up with the sensation of choking for 18- 
31 %, restless sleep or sweating in 50 % and dryness of mouth in 74 % of patients
(Guilleminault & Bassiri 2005; Rundo 2019).
2.3.5 Insomnia
Insomnia is a common sleep disorder that is estimated to affect 4 to 35 % of the
population depending on the criteria used (Kay-Stacey &Attarian 2016). Further, co-
morbid OSA and insomnia (COMISA) prevalence estimates range from 6.7 (Lang 
et al. 2017) to 27-85 % (Sweetman et al. 2017). Insomnia is usually characterised as 
having difficulty initiating sleep, maintaining sleep, or waking up too early or being
unable to return to sleep (Sateia 2014). In recent studies, COMISA has emerged as
a significant cluster of OSA, usually associated with the female gender (Sweetman
et al. 2017). 
The COMISA cluster has been linked to a higher risk of CVD, pulmonary 
diseases, and psychiatric comorbidities (Anttalainen et al. 2019; Saaresranta et al.
2016). It is also associated with significant daytime functional, social, and
occupational impairments, and a reduced quality of life (Morin et al. 2006). Recent
research further indicates that patients with COMISA are less likely to accept and
use CPAP therapy compared to those patients without insomnia (Eysteinsdottir et al.
2017; Wickwire et al. 2010). Therefore, it has been suggested, that in COMISA, 
patient’s insomnia should be treated first, in order to increase patient acceptance of
CPAP therapy (Luyster et al. 2010; Sweetman et al. 2017).
2.3.6 The effects of gender
Women do report different symptoms of SDB than men do, and women also often
suffer from daytime fatigue, anxiety or depressive symptoms, lack of energy,
insomnia, and morning headaches (Kapsimalis & Kryger 2002). In addition, women
with SDB have lower AHI, less severe hypoxemia, and a greater peripheral fat mass
than men (Sforza et al. 2011). The diagnosis of SDB is often delayed in women,
partially because of the different variation in symptoms compared to those in men
(Lindberg et al. 2017; Young et al. 1996). Even though women have lower AHI, they
do appear to be more symptomatic at lower levels of AHI when compared to men
(Young et al. 1996). 
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In part, this difference could be explained by the fact that women have more 
prolonged partial upper airway obstruction (UAO), which is not implemented in AHI
value, but can cause symptoms similar to OSA (Anttalainen et al. 2016; Mohsenin 
2001; Saaresranta et al. 2015). Prolonged partial upper airway obstruction is now
considered to be a relevant part of the SDB family, and recent research is implying
that prolonged UAO is more than just mild OSA (Anttalainen et al. 2016). To 
emphasise the different phenotype for female SDB, women also have more REM
related SDB (Kapsimalis & Kryger 2002), and their prevalence of positional
obstructive sleep apnoea (POSA) may differ from that in men.
Some studies also indicate that women have less POSA than men (Basoglu & 
Tasbakan 2018), whereas other studies suggest that POSA in women is more common
regardless of SDB severity (Heinzer et al. 2018). Women have less SDB than men, but
after menopause the prevalence of SDB doubles (Anttalainen et al. 2006; Bixler et al.
2001). In menopause, women go through an array of changes, including hormonal
decline in oestrogen and progesterone levels, leading to vasomotor changes, mood
alterations, and often also sleep disturbances (Takahashi & Johnson 2015). Not only
SDB prevalence, but also the prevalence of other sleep disturbances, such as restless
legs syndrome and insomnia, increases after menopause (Baker et al. 2018). The
definite underlying mechanisms are not fully understood, but studies have indicated
that it is an complex interaction that involve aging, hormonal changes, visceral fat
redistribution, and pharyngeal collapsibility (Perger et al. 2019).
2.4 Diagnosis
The diagnosis of SDB is based on thorough clinical examination, involvement of
appropriate symptoms in patient history, and most importantly, polysomnography 
(PSG) or cardiorespiratory polygraphy (PG) (Kapur et al. 2017). Several
questionnaires have been developed for screening SDB, and if the possibility is high,
then PG or PSG should be performed. PSG and PG are expensive tests, and the
workload is substantial, therefore screening is advised (Kapur et al. 2017). The most
common questionnaire for screening is STOP-BANG, which includes four
subjective elements (STOP: Snoring, Tiredness, Observed apnoea and high blood
Pressure) and four demographic items (BANG: BMI, Age, Neck circumference,
Gender). It is well validated for determining the possibility of moderate-to-severe
OSA (Nagappa et al. 2015).
Cardiorespiratory polygraphy
Cardiorespiratory polygraphy (PG) is the most common examination utilised for 
determining SDB in Nordic countries, whereas in most other parts of the world
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polysomnography (PSG) is the most applied method. In PG, sleep stages cannot be
determined, as the set-up does not include an electroencephalogram (EEG). PG
usually includes measurements of electrocardiography (ECG), inspiratory flow
pressure with differential pressure sensor connected to nasal prongs, abdominal and
thoracic movement analysis with belts with respiratory inductive plethysmography 
(RIP), and determination of sleeping position. In addition, electromyographic
(EMG) sensors may be connected to both the patient’s legs to m. tibialis anterior to
determine sleep-related movement disorders. If PG is performed in a hospital ward,
transcutaneous carbon dioxide partial pressure can be measured based on the
diffusion of carbon dioxide through tissue and skin, with the help of a heated
electrode. Video recording can also be included.
Arterial oxyhaemoglobin saturation (SaO2) is measured with a finger probe pulse
oximetry. The advantage of preferring PG is the possibility to perform the study as 
ambulatory and to decrease the costs and workload of the analysis. Basic PG is
usually sufficient to diagnose SDB in adults (Kapur et al. 2017). In addition, in PG,
the AHI values are approximately 30 % lower than in PSG due to a partly different
scoring criteria and missing data on sleep staging. Hence wake time is included in
PG (Escourrou et al. 2015; Hedner et al. 2011).
Polysomnography
The set-up of PSG includes the same measurements as PG, with sensors added to
determine sleep stages. This process allows a more detailed diagnosis of a wider
range of sleep disorders. In PSG, at least three electroencephalography (EEG) leads,
two electrooculography (EOG) leads, and an EMG lead for the m. submentalis are
attached. PSG allows an evaluation of wake, arousals, and sleep stages, usually in
30-second epochs, and the breathing patterns associated with each of them. In
addition, with the help of EMG leads, bruxism can be detected. Video recording is
often included in the PSG set-up.
2.5 Subtypes of SDB
2.5.1 Obstructive sleep apnoea
The most common type of SDB is obstructive sleep apnoea, characterised by 
episodes of total or partial pharyngeal collapse during sleep leading to pauses in
breathing. This obstruction results in desaturations of blood oxygen concentration,
and sleep fragmentation. The diagnosis is made using either PSG or PG (Kapur et
al. 2017). In PG, apnoea is defined as a decrease in breathing amplitude of 90 % for 
10 seconds, while attempts to breathe continue. Efforts of breathing are detected as
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movements in thoracic and abdominal belts. In addition, desaturation of 3 % or more
from the baseline level in arterial oxyhaemoglobin saturation must be present for the
event to be considered as apnoea. Hypopnoea is defined as a decrease in breathing
amplitude by 30 % or more from the normal stable level and combined with a 
desaturation of 3 % in arterial oxyhaemoglobin saturation. The sleeping time is
divided by the sum of these two events, giving a total AHI. The patient is diagnosed
with obstructive sleep apnoea if AHI >5/h. OSA is considered as mild if AHI<15/h. 
Values of 15-29/h result in moderate OSA, and values ≥30/h are considered as severe
OSA. If the patient has daytime symptoms, then the condition is called obstructive
sleep apnoea syndrome (OSAS) (Berry et al. 2012).
2.5.2 Prolonged partial upper airway obstruction
In prolonged partial upper airway obstruction, the airways do not collapse 
completely, but the air stream is affected and diminished for at least 1-3 minutes, but
it can persist as long as 60 minutes, resulting in similar symptoms as in OSA. In 
polygraphy, the air flow in the respiratory channel is flattened as seen in Figure 4. In
addition, it has been shown that during prolonged UAO, transcutaneous carbon 
dioxide (PtcCO2) levels increase higher than in other SDB forms or during steady
breathing (Figure 5) (Rimpilä et al. 2015). Upper airway obstruction is more
common in women than it is in men, and it is often disregarded when determining
treatment considerations (Anttalainen et al. 2016; Polo-Kantola et al. 2003; 
Tenhunen et al. 2013). It has been estimated, that 17.7 % of subjectively healthy 
postmenopausal women suffer from UAO (Polo-Kantola et al. 2003), and from a
clinical cohort of females with suspected SDB, UAO was found in 66.1 % of
postmenopausal and 50.9 % of premenopausal women (Anttalainen et al. 2006).
Only recently, has the significance of this phenomenon been understood, and
recent studies have shown that clinically, the future risks of UAO may be as high as
other SDB (Saaresranta et al. 2015). The consensus of the reference values or clinical
practice is still under investigation, but recent studies do point in the direction that
this issue should be taken as seriously as other SDBs and treated just as efficiently
(Anttalainen et al. 2010a; Saaresranta et al. 2015).
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Figure 4. Prolonged upper airway resistance in polygraphy. The red square shows normal
breathing pattern and flow amplitude which is flattened in the latter patterns that illustrate
upper airway resistance. Reprinted with a permission of Sari-Leena Himanen.
Figure 5. Example of polygraphy (PG) profile during wake, upper airway obstruction (UAO)
illustrated with flow limitation, hypopnoea, normal breathing and wake. The numbers 1-
5 illustrate different types of breathing and the typical level of transcutaneous carbon 
dioxide (PtcCO2) during them. Arterial oxyhaemoglobin (SaO2) concentrations are 
illustrated at the bottom. Reprinted from Rimpilä et al. 2015 with a permission of
Respiratory Physiology & Neurobiology.
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2.5.3 Mild sleep apnoea
Traditionally, mild sleep apnoea is diagnosed, if AHI is 6-14/h (Berry et al. 2012).
In the HypnoLaus study, the prevalence of mild symptomatic sleep apnoea varied
according to gender and age. In men under 60, the prevalence was approximately 40
% and in women the same age, it was over 30 %. In men over 60, the prevalence was
approximately 25 % and in women, it was over 40 % (Heinzer et al. 2015). In
addition, especially for mild sleep apnoea measured with portable home monitoring,
the night-to-night variation in AHI was high (Prasad et al. 2016; Stöberl et al. 2017).
Mild obstructive sleep apnoea is thought to have less of an impact on comorbidities
or other risks, and it is usually left untreated or treated with lifestyle changes,
positional treatment, or a mandibular device (Tingting et al. 2018).
However, recent studies have discovered, that patients with mild sleep apnoea have 
the same risks for comorbidities as do patients with a more severe condition (Anttalainen
et al. 2010a; Saaresranta et al. 2015). It is currently discussed whether mild sleep apnoea
should be treated as efficiently as more severe conditions, in order to prevent the
comorbidities and rising costs that come with the condition. As we have broadened our
perspective of sleep apnoea with more knowledge of different phenotypes being
included in this umbrella term, the importance of AHI is going to diminish in the future. 
Patients previously destined to fall into a “mild” category, regardless of detrimental
symptoms and hence left untreated, can be evaluated more sufficiently using this tailored
approach. One innovative suggestion is to use the PALM scale (Pcrit, Arousal threshold,
Loop gain and Muscle responsiveness scale) (Eckert 2018), but it has been criticised for
demanding excessive amount of data and measurements that cannot be performed in
wide clinical settings (Bonsignore et al. 2017).
2.5.4 SDB related to REM sleep
SDB related to rapid eye movement (REM) sleep can be diagnosed with PSG, where
respiratory events can be seen along with their association to the REM stage of sleep.
If the sleep study is performed with PG, sleep stages are not visible due to a lack of
EEG. With PG, REM related SDB can be diagnosed only by using the assumption,
that apnoeas are seen during the hours fit for REM sleep (Berry et al. 2012). The 
REM stage of sleep occurs mainly in the early hours of morning at the end of a night.
If the scorer does not recognise these stages, then the condition can be masked, due
to the fact, that AHI dilutes when the value is calculated by using the entire time in
bed (Berry & Gleeson 1997). 
REM OSA is common, evaluations being 10–40.8 % of patients referred to
investigations for suspected sleep apnoea (Acosta-Castro et al. 2018; Nisha Aurora
et al. 2018). In REM sleep, genioglossus muscle activity and pharyngeal dilator
muscle control are decreased due to changes in the neurotransmitters, leading to an
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increased possibility of upper airway collapse (Grace et al. 2013). Moreover, REM
sleep is related to haemodynamic variability and an increase in sympathetic activity
and myocardial demand. Therefore respiratory events during REM sleep are thought
to be longer and more frequent, leading to deeper oxyhaemoglobin desaturation than
events during non-REM (NREM) sleep (Penzel et al. 2016; Somers et al. 1993). 
Based on the aforementioned, REM OSA has thus been associated with hypertension
(Appleton et al. 2016), impairments in glucose metabolism (Acosta-Castro et al.
2018; Chami et al. 2015), and cardiovascular disease (Acosta-Castro et al. 2018; 
Aurora et al. 2018; Aurora &Punjabi 2013). 
REM OSA is more common in women than in men (O’Connor et al. 2000), 
leading to women being under-treated for OSA based on the total AHI. Traditional
AHI reflects NREM-AHI, which is predominant in men, but it disregards REM-AHI. 
Under-treatment of OSA, therefore, may contribute to an increase in risk for
cardiovascular disease in women. In addition, the standard use of NREM-AHI
emphasises the importance of using CPAP throughout the entire night to cover the
apnoeas related to REM sleep, which is present in the latter part of the night (Won 
et al. 2019).
2.5.5 Central sleep apnoea
Central sleep apnoea (CSA) does not originate from obstruction of the airways, but 
from the central control of breathing. The prevalence is estimated to be 0.9-4 % of
population level (Donovan & Kapur 2016; Heinzer et al. 2015). Central events are 
currently thought to represent an instability of the breathing pattern and it may
provoke obstructive events (Dempsey et al. 2014). In CSA, high loop gain is present,
resulting in CO2 concentrations’ decreasing beyond the apnoeic threshold, resulting
in the apnoea persisting until the CO2 concentration has elevated to a normal level
(Naughton 2010; White 2005; Younes et al. 2001). In PSG or PG, central apnoeas
are seen as a flat line in the respiratory channel, but contrary to OSA, there are no
efforts of breathing visible in the abdominal or thoracic belts (Randerath et al. 2017). 
CSA can be a result of cardiovascular (Arzt et al. 2016), internal or neurological
disorders (Lipford et al. 2014; Nachtmann et al. 1995; Perks et al. 1980), or it can
emerge under CPAP therapy (Morgenthaler et al. 2006) or during opioid use
(Guilleminault et al. 2010), or at high altitudes (Bloch et al. 2015). 
2.6 Treatment of SDB
In the imminent future, the treatment of SDB is most likely going to change.
Nowadays, the gold standard of treatment is CPAP therapy, and it is commenced in
all patients who have moderate to severe sleep apnoea (AHI>15/h) (Kapur et al.
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2017; Sateia 2014), and for patients with mild sleep apnoea if they have severe
symptoms or are not candidates for a mandibular device. However, there are still
other treatments that can be used if CPAP therapy is unsuccessful or if the SDB is
mild (Tingting et al. 2018). In the future, the phenotype for patient suffering from 
SDB, will dictate the right treatable trait, and those patients can then be treated
accordingly (Bonsignore et al. 2017; Saaresranta et al. 2016).
Continuous positive airway pressure (CPAP)
treatment
Nasal CPAP was invented in 1981 by the Australian physician, Colin Sullivan, and 
his co-workers (Sullivan et al. 1981). Since that invention, CPAP has been the gold
standard for treating SDB, especially obstructive sleep apnoea (Sullivan et al. 1981). 
CPAP is used during sleep, and it supports the patient’s breathing by delivering a
constant airflow into the airways, creating a pillar of air, that then mechanically
keeps the upper airways open. The air is delivered via a nasal mask, which is linked
to the actual CPAP device via a long flexible tube (Sullivan et al. 1981).
CPAP therapy reverses SDB and normalises the metabolic factors that influence
breathing. The treatment is efficient, but adherence remains a problem and is the 
most important factor that results in discontinuing the therapy. In twenty years, the 
adherence has not improved, and non-adherence continues to remain in 34 % of
patients (Rotenberg et al. 2016). A lot of technical efforts have been undertaken to 
improve adherence. Masks have improved in recent years, along with advances in
CPAP device technology that have enabled smaller, quieter, and more convenient
devices being available for patients (Patil et al. 2019). 
The positive effects of CPAP therapy have been demonstrated in numerous
studies over thirty years (Gay et al. 2006), but the adverse effects continue to be
vigorously studied to this day. There are mixed results, both positive and negative,
for the countless variables (Bonsignore et al. 2019a; Jennum & Kjellberg 2011). All
in all, the results have been sustained more on the positive side, and CPAP therapy
still remains the best choice today, along with lifestyle changes, for treating patients
with moderate to severe SDB.
Non-CPAP treatment
CPAP therapy remains to be the most efficient treatment for moderate-to-severe
OSA, but there are other treatments that can be used along with CPAP therapy, or if
CPAP therapy is unsuccessful. Especially lifestyle counselling should be offered to
all SDB patients regardless of other treatments.
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2.6.2.1 Weight loss
It has been estimated that 70 % of patients with SDB are obese (Young et al. 1993)
Obesity and OSA have a complex bidirectional alliance (Peppard et al. 2000)
described in Figure 6.
Figure 6. The bidirectional alliance of SDB and obesity
Previously, it was thought that treating sleep deprivation in SDB patients resulted in
a more reasonable diet, greater physical activity, and finally, weight loss.
Unfortunately, this seems not to be the case overall (Joosten et al. 2017; Tachikawa
et al. 2016). Over the course of long-term CPAP therapy, weight tends to remain the 
same or even increase, especially in young obese OSA patients and in women
(Myllylä et al. 2016; Redenius et al. 2008). Yet weight loss has been proven to
influence SDB positively and in some cases even cure OSA (Joosten et al. 2017;
Tuomilehto et al. 2009). In addition, weight loss leads to improvement in overall
cardiovascular risk and may lead to additional benefits for SDB symptoms (Chirinos
et al. 2014). Even small reduction in weight is associated with improvement of OSA;
10 % reduction in body weight results in an approximate decrease of 26/h to 32/h in 
AHI (Peppard et al. 2000). Therefore, all efforts to manage OSA must involve 
lifestyle counselling and support for weight loss along with ongoing CPAP therapy
(Joosten et al. 2017).
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2.6.2.2 Lifestyle changes: Smoking, alcohol, and exercise
Lifestyle changes are a key factor when treating SDB as noted above (Joosten et al.
2017). The prevalence of smoking is high among patients with OSA, even reaching
35 %, when in the overall population, only 18 % smoke. In addition, smokers are 2.5
times more likely to have OSAS (Kashyap et al. 2001). Male patients smoke more 
than female OSA patients do (Varol et al. 2015), and further, both OSA and smoking
are well-known risk factors for metabolic disorders (Craig et al. 1989; Zhu et al.
2017). Various compounds in cigarette smoke increase oxidative stress and systemic
inflammation, thus contributing to the formation of metabolic disorders (Ambrose &
Barua 2004). Smoking also causes swelling of the mucosa possibly due to increased
calcitonin gene-related peptide (CGRP) related to neurogenic inflammation, and 
exacerbation of any upper airway collapse at the level of the uvula, resulting in a 
worsening of UAO (Kim et al. 2012). Therefore, smoking cessation for these patients 
or those at risk for OSA is essential.
Kolla et al stated in their own meta-analysis that given alcohol consumption,
AHI increased, mean SaO2 reduced, and there was an increase in respiratory event
duration, and a decrease in nadir SaO2 following two or three standardised drinks
(Kolla et al. 2018). Alcohol consumption should be kept to a minimum in patients
with SDB.
Exercising affects SDB, even if it does not affect weight (Carneiro-Barrera et al.
2019). In the Wisconsin Sleep Cohort Study, hours of exercise were associated with
a reduced incidence of mild and moderate OSA, independent of other confounders
such as BMI (Awad et al. 2012). One hypothesis suggests that moderate exercise 
reduces fluid accumulation in the legs, thereby decreasing nocturnal fluid shift. 
When lying down, fluid redistributes to the neck which may lead to increased
pressure in tissues surrounding the upper airway, reducing its size and increasing its
collapsibility (Redolfi et al. 2015).
2.6.2.3 Mandibular advancement device
Mild SDB can be treated with a mandibular advancement device (MAD),
constructed by a dentist. A wide variety of devices are available, but all MADs are 
worn intraorally during the night. They prevent upper airway collapse by holding the
mandible and tongue forward and increasing the antero-posterior dimensions of the
oropharynx (Cistulli et al. 2004). In addition, it is assumed, that the effect of MAD
is also associated with an increase in lateral dimensions, i.e., the lateral displacement
of the parapharyngeal fat pads from the airway, an increase in lower anterior facial
height, a raised position of the hyoid, and anterior positioning of the base of tongue
muscles (Chan et al. 2010). For patients who are intolerant of CPAP therapy, MAD 
can be effective in reducing the AHI compared to non-treatment. 
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In patients with only mild OSA, CPAP and MAD are similarly effective therapy
options. There is a significant heterogeneity between patients in their response to
MAD therapy, which can, in part, be explained by the severity of OSA at baseline
(Sharples et al. 2014). OSA patients usually prefer MAD over CPAP, but more than
one-third of the patients will have minimal or no major reduction in AHI with MAD.
Based on a recent meta-analysis, the responders had lower age, lower BMI, smaller
neck circumference, lower AHI, an anatomic variation such as a retracted maxilla
and mandible, a narrower airway or a shorter soft palate than non-responders (Chen
et al. 2020).
2.6.2.4 Surgical interventions
When a patient suffers from SDB as a result of anatomical abnormalities, surgical
interventions can be successful. Surgical options for the treatment of OSA include
tonsillectomy and adenoidectomy, uvulopalatopharyngoplasty (UPPP),
radiofrequency ablation, and maxillomandibular advancement (MMA) (Wray &
Thaler 2016). The past decade, MMA has been revealed to be the most popular and 
effective surgical therapy, and offer the most active research (Awad et al. 2019). 
UPPP has been reported to reduce AHI by approximately 33% twelve months after
surgery, but still, it is primarily indicated for those patients with an anatomic basis
for obstruction (Strollo et al. 2015).
In morbidly obese patients, gastric bypass surgery is considered as a valid
treatment of SDB, but the research evidence remains limited (De Raaff et al. 2018). 
Hypoglossal nerve stimulation (HNS) was already successfully reported in 2001
(Schwartz et al. 2001). The target of the stimulation is activating the genioglossus
muscle and thus improve nocturnal breathing in OSA patients. The stimulator is a
pacemaker-like pulse-generator with two parts: The generator is implanted to detect
ventilator effort, and a stimulation lead stimulates the branches of the hypoglossal
nerve, predominantly the genioglossus muscle (Wray & Thaler 2016). Therapy has
been proven to be effective, however, only a well selected OSA patients; hence 
broader clinical use still remains to be seen (Wray & Thaler 2016).
Effects of CPAP therapy
2.6.3.1 Weight
It has been revealed in recent years that treating SDB with CPAP therapy does not
result in weight loss (Myllylä et al. 2016; Redenius et al. 2008) nor increase a 
patient’s physical activity during the day (Bamberga et al. 2015). The assumption, 
therefore, today is that patients using CPAP therapy remain the same weight or even
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gain weight, especially the young and women (Drager et al. 2015; Ou et al. 2019).
The regulation of energy balance in OSA is complex and multifactorial, involving
hormonal regulation of hunger, food intake, and energy expenditure that affects the
metabolism and physical activity. CPAP therapy may reduce energy expenditure, but
it does not result in any compensatory increase in physical activity (Shechter 2016).
The toning down of sympathetic overdrive during the night in SDB results in less
energy consumption and, therefore, a weight gain (Bamberga et al. 2015). Tachikawa
et al. discovered that three months of CPAP therapy reduced the basal metabolic rate
thereby favouring a positive energy balance in terms of energy expenditure
(Tachikawa et al., 2016). Exercising habits and food consumption seem to remain
similar compared to those before CPAP therapy, although in women a modest
increase in recreational activity during CPAP therapy has been reported (Batool-
Anwar et al., 2014).
2.6.3.2 Mood
SDB causes a variety of mental symptoms (Garbarino et al. 2018a). Especially in
women, these symptoms can be severe, and initially, they can be mistaken for and 
thus treated as mental illnesses. Depressive symptoms are present in a quarter of
patients suffering from SDB (Ramar & Guilleminault 2006) and it has been
suggested in many studies that treating SDB with CPAP alleviates these symptoms 
dramatically (Lang et al. 2017; Millman et al. 1989; Sánchez et al. 2001). In addition,
anxiety is commonly present, but the effects of CPAP therapy on anxiety have not
been studied as thoroughly as the depressive symptoms.
There are, however, some indications that CPAP therapy alleviates anxiety
(Sánchez et al. 2001); yet, in a recent meta-analysis, there was no significant
improvement in anxiety with CPAP therapy (Zheng et al. 2019). SDB is
overrepresented in the population with severe mental illnesses (Nikolakaros et al.
2015). Of patients with schizophrenia, 15–48 % have SDB (Kalucy et al. 2013), and 
these symptoms are often discarded. CPAP therapy seems to improve the cognitive
impairment of schizophrenia (Myles et al. 2019), and alleviate both the symptoms of
SDB and the psychiatric disorder (Gupta & Simpson 2015). Bipolar disorder, 
however, has been described to worsen during CPAP therapy, and therefore, these 
patients should be treated with greater caution (Aggarwal et al. 2013).
2.6.3.3 Leptin
Leptin is an adipocyte-secreted hormone that controls food intake and stimulates
energy expenditure mainly through the neuronal pathways in the brain (Auwerx &
Staels 1998). Leptin crosses the blood–brain barrier (BBB) via a receptor-mediated
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endocytosis mechanism as illustrated in Figure 7. The signalling interactions have
been revealed to be complex. In addition, leptin is produced in various organs. 
Circulating leptin concentrations are correlated with the amount of body fat and are
thought to reflect energy status (Auwerx & Staels 1998).
Figure 7. Activation of Janus Kinase (JAK) occurs by transphosphorylation (green circles) and 
subsequent phosphorylation of tyrosine residues in the cytoplasmic region of the Ob-
receptor. Phosphorylation of JAK leads to phosphorylation of signal transducers and
activators of transcription (STAT’s), which allows their dissociation from the receptor.
Active STAT’s translocate to the nucleus to regulate gene expression.
If gene controlling leptin production is absent or violated, the result is excessive
eating and morbid obesity, as has been observed in ob/ob knock-out mice, who lack
the gene that enables leptin formation, resulting in leptin deficiency (Zhang et al. 
1994). The mice become obese and develop multiple comorbidities, such as diabetes, 
and thus that species is widely used in research (Münzberg & Morrison 2015). In
humans, the lack of an ob gene is extremely rare, but as humans gain weight, or get
older, leptin resistance emerges and the feelings of satiety demand escalating leptin
concentrations (Zhou & Rui 2014).
The precise underlying mechanism of leptin resistance is still unknown, but it
might be the result of changes in the leptin receptors in the hypothalamic area, 
resulting in leptin being unable to penetrate the BBB (Myers et al. 2008). Resistance
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at the BBB level seems to be multifactorial and according to yet another theory leptin
transporters are increasingly saturated during obesity, and the transporters reach full
capacity at a leptin concentration 40 ng/ml, thereby blocking the access of leptin to
the central nervous system (CNS), resulting in continuous weight gain (Banks et al.
2000).
In patients who are suffering from OSA, leptin concentrations are higher than in
the controls, regardless of age or BMI (Considine et al. 1996; Thomas et al. 2000). 
This circumstance is thought to be a result of hypoxia during sleep or sleep
fragmentation, both of which have been shown to elevate leptin concentrations in 
mice (Harsch et al. 2003; Taheri et al. 2004). This result could be associated with the
fact that leptin is a powerful ventilatory stimulant, independent of its metabolic
effects. It increases ventilation through receptors in CB (Caballero-Eraso et al. 2019;
O’Donnell et al. 1999) and acts in the medullary centres that regulate the responses
to hypercapnia (O’Donnell et al. 1999).
The effect of CPAP therapy on leptin concentrations has been broadly studied,
leading to rather conflicting results. Most studies reported a decrease in leptin
concentrations during CPAP therapy (Pan & Kastin 2014). However, these study
samples were rather small and consisted primarily of men. It is also known that leptin 
concentrations are gender related (Akilli et al. 2014); therefore, the results for men
should not be generalised to women. The results in some of the previous studies on
the CPAP effect are presented in Table 3.
Table 3. Some previous studies of CPAP therapy and change in leptin concentrations.
Author Year N Gender Duration
(months)
Result
Chin 1999 10 All male 6 Decreased
Ip 2000 30 M 27, F 3 6 Decreased
Harsch 2004 30 All male 2 Decreased
Sanner 2004 86 M 69, F 17 6 Decreased among high adherence 
patients
Yee 2006 14 M 11, F 3 18–36 Decreased
Drummond 2008 98 All male 6 First decreased, then increased
Dorkova 2008 32 M 27, F 5 2 No change
Cuhadaroglu 2009 31 All male 2 Decreased
Macrea 2010 10 All male 11–39 No change
Sanchez 2012 36 All male 3 Decreased
Yosukaya 2015 31 All male 3 No change
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2.6.3.4 Insulin-like Growth Factor 1 (IGF-1)
IGF-1 is expressed mainly in the liver, but it can also be produced in almost every
tissue of the body (Ohlsson et al. 2009). The secretion of IGF-1 is dependent on
pulsatile growth hormone production from the anterior pituitary gland and portal
insulin exposure (Münzer et al. 2010). It is considered to be an important growth 
factor. OSA is thought to be associated with a significant decrease in serum IGF-1 
concentrations (McArdle et al. 2007; Ursavas et al. 2007). A growing body of
evidence from the clinical research indicates that CPAP therapy appears to increase
IGF-1 levels in OSA patients (Chen et al. 2015). Some of the previous studies and 
their results are presented in the following Table 4.
Table 4. Previous studies on CPAP therapy and IGF-1 concentrations. Modified from Chen et al.
2015.
Author Year N Gender Duration 
(Months)
Result
Grunstein
Brooks
Meston
Lindberg
Barcelo (EDS)
Barcelo (NON-EDS)
Makino
1989
1994
2003
2006
2008
2008
2012
43 
9 
52 
11 
20 
15 
18 
All male
M 7
All male
All male
All male
All male
All male
3 
4 
1 
6 
3 
3 
17.5 
Increased
No change
Small increase
Increase 
Increase 
Increase 
Increase 
2.6.3.5 Comorbidities and medication
The effects of OSA treatment on various comorbidities has been broadly studied, but 
mainly as comorbidity prevalence before and after therapy initiation. Principally the 
treatment for the comorbid patient group has been CPAP, as comorbidities are seen
as an increased risk of overall morbidity, thus leading to choosing the most effective
therapy for patients who have multiple comorbidities (Bonsignore et al. 2019a). 
Along with these comorbidities come increased expenses for medication, so
therefore, the effects of CPAP therapy have been of particular interest.
2.6.3.6 Cardiovascular comorbidities
The effects of CPAP on cardiovascular comorbidities is widely studied. The effect
of CPAP therapy on hypertension has been studied the most and by using various
methods, but as the knowledge has mounted, the conclusion is that the effect is
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positive, although minor (Pengo et al. 2020). However, these results have possibly
been controversial due to their effect being dependent on adherence to CPAP, the 
severity of SDB, and the baseline values of blood pressure (Haentjens et al. 2007). 
The same confounders have been discovered to influence more detrimental
cardiovascular outcomes such as myocardial infarction, stroke and cardiovascular
mortality (Hudgel 2018).
Some studies also have indicated that cardiovascular morbidity and mortality are
normalised with CPAP therapy (Marin et al. 2010; Myllylä et al. 2019), while others
have reached the conclusion that CPAP has no protective effect (Yu et al. 2017). In
one recent review, there were no indications that CPAP therapy could improve CV
outcomes (Labarca et al. 2020). However, in another review, CPAP was found to
have a minor effect on CV outcomes for patients with coronary artery disease in
small studies, but not in randomised controlled trials (Wang et al. 2018). 
Arrhythmias are common among patients with SDB, and CPAP therapy seems to
decrease recurrent arrhythmias (Deng et al. 2018). Patients with heart failure and 
OSA have also been shown to benefit from CPAP therapy. Treatment reduced rates
of hospitalisations, but again, the effect depended on adherence (Kasai et al. 2008).
2.6.3.7 Metabolic comorbidities
As discussed earlier, metabolic comorbidities arise from the union of obesity and
SDB. Therefore, treating SDB with CPAP therapy should at least in part have
positive effects. Yet, on the other hand, CPAP therapy alone does not influence the
visceral adipose tissue (Chen et al. 2020) and the metabolic instabilities that obesity
creates (Sivam et al. 2012). Still, there are indications that CPAP therapy can have a
positive influence on metabolic disturbances in patients with insulin resistance
(Abud et al. 2019). However, diabetes and OSA have a bidirectional link. Thus,
treating patients with OSA and diabetes with CPAP, has been proven to reduce such
consequences, as neuropathy, nephropathy, and retinopathy, while the glycaemic
blood concentrations are not affected (Zhu et al. 2018). This finding has led to a
discussion on screening SDB of patients with diabetes to prevent severe
complications.
2.6.3.8 Respiratory comorbidities
Recent studies indicate that CPAP therapy has a protective effect on patients with
COPD and OSA overlap syndrome (Marin et al. 2010; Stanchina et al. 2013), but 
that knowledge is still scarce. Phenotyping of SDB patients is thought to bring about
better understanding and more knowledge of when to treat overlap patients. Similar
situation exists with asthma and SDB patients. There are studies both in favour of 
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(Kauppi et al. 2016) and against (Ng et al. 2018) the positive effect of CPAP therapy
on asthma symptoms, but it is still thought that in severe or poorly controlled asthma,
CPAP therapy can be beneficial (Davies et al. 2018).
2.6.3.9 Medication
Patients with SDB, especially OSAS, have a higher risk of comorbidities (Somers et
al. 2008) leading to an increased use of health care as early as seven years before the 
diagnosis (Jennum et al. 2014). In one study, risk of lost work days was higher as
early as five years before SDB diagnosis in women and one year in men, thus
increasing health care costs (Sjösten et al. 2009). In addition, all-cause mortality is
shown to be higher in patients with OSA, and CPAP therapy seems to reduce that
risk in men, but not in women (Jennum et al. 2015). 
Medication use is higher in patients with OSA (Jennum & Kjellberg 2011), 
perhaps due to a greater number of comorbidities, but the effect of CPAP on 
medication use remains controversial. Some studies have shown that the overall
costs of medication are reduced with CPAP (Tan & Marra 2006), while others have
failed to show any reduction, and instead an increase in medication costs (Jennum &
Kjellberg 2011). 
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3 AIMS OF THE STUDY
This study sought to evaluate the effects of long-term CPAP therapy on various
factors, especially those that influence weight and medication use. In addition, the
study wants to find the predictors of changes in weight and the effects of gender on 
these issues. The following three specific objectives thus were:
1. Evaluate whether long-term CPAP therapy for SDB can alleviate patients’ 
SDB symptoms, leading to a healthier lifestyle and better weight
reduction.
2. Evaluate the effect of long-term CPAP therapy on weight, leptin, and IGF-
1 concentrations in obstructive sleep apnoea.
3. Evaluate the effects of long-term CPAP therapy on medication use for
comorbidities in females who have sleep apnoea or prolonged partial
upper airway obstruction.
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4.1.1 
4 PARTICIPANTS AND METHODS
4.1 Participants 
Study I and II
Participants in Studies I and II were consecutive patients who were referred to the 
Department of Pulmonary Diseases at the Turku University Hospital to confirm or
rule out their instance of SDB. The cohort was prospectively collected from March
2004 to October 2006, and totalled 223 patients, of which 101 were men (45.3 %),
and 122 were women (54.7 %). After three years of follow-up, the study population 
was divided into two groups: 1) CPAP users, who had used CPAP therapy for three
years at least four hours per day and 2) non-users, who did not commence CPAP at
the beginning or had discontinued the use before their three-year follow-up visit.
Among the non-users, there were 20 patients (11 males, 9 females) who had AHI< 
5/h; however, all had symptoms suggesting OSAS. Of the cohort, 149 patients (66.8 
%; 65 males, 84 females) participated in the follow-up visit. Out of those who
participated, 76 patients (51.0 %; 32 males, 44 females) were categorised as CPAP
users and the rest as non-users (n=73; 33 males, 40 females).
Among the non-users, 20 patients had AHI < 5/h and CPAP therapy was not
suggested. Further, 29 patients refused to commence CPAP treatment despite the
pulmonologist’s recommendation. Additionally, seven patients started the therapy,
but used it for less than three months, five patients used CPAP for 3-11 months, and
nine used it for 12-24 months. There were some missing values in the questionnaires
and blood values; therefore, the number of participants differed in Studies I and II,
as explained later in detail. The flowchart for the patient selection is described in
Figure 8.
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Participants and Methods 
Figure 8. Flow chart of the study population in study I and II. Reprinted from original publication II
with permission of Sleep and Breathing.
4.1.2 Study III
In this retrospective study, only females were included. Patients were selected from
the pulmonary clinic database of 601 consecutive females who were referred to the 
Department of Pulmonary Diseases in Turku University Hospital from 1994 to 1998
for suspected SDB. They all had symptoms suggesting sleep disordered breathing,
such as snoring, daytime sleepiness, or apnoeas witnessed during sleep.
From these 601 patients, Static-Charge-Sensitive bed (SCSB) recordings were
available for 469 (78 %) patients and SDB was found in 368 patients (65 %). CPAP
therapy was initiated with 137 women, and 231 women were considered as the
controls, as they did not initiate CPAP. Hospital records were retrospectively 
screened for information on age, BMI, neck circumference, and smoking status. This
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information was available from 587 (97.7 %) of the original patients. Data on CPAP
use were derived from the hospital records at the time of the sleep study, and then
after one or two years of CPAP use. If the patient had used CPAP for more than four
hours per night, she was considered a CPAP user. The controls did not start CPAP 
therapy or discontinued therapy within one year of treatment. National Social
Insurance Institution medication data were available from 1993 onwards. Therefore, 
only those patients, whose sleep study was undertaken in 1996-1998 were included 
in the study to allow for use of medication data three years before CPAP initiation
or the sleep study. This criterion resulted in 66 CPAP users and 122 controls as seen
in Figure 9.
Original female cohort Sleep 
study performed in 1994–1998601 
469 
368 
137 
66 
231 
122 
Controls
Sleep study available
Diagnosis of sleep 
disordered breathing
CPAP 
initiated
Sleep Study Sleep Study performed 
performed in in 1996–1998
1996–1998
Figure 9. Flow chart of patient selection in study III. Modified from Original Publication III.
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4.2.1 
Participants and Methods 
4.2 Methods
In Studies I and II, during the baseline study at the ward, patients filled in
questionnaires in the evening, after a standardised hospital meal. During the night,
they underwent an overnight PG, and in the morning their blood was drawn after an
overnight fast. In addition, their height and weight were measured by a nurse, and
the BMI calculated. Questionnaires, blood samples, and measurements of BMI were
repeated after three years, but the PG was not repeated. In addition, some patients
had their waist and hip circumference measured in order to evaluate visceral fat.
The sleep study
4.2.1.1 Cardiorespiratory polygraphy (Studies I and II)
All patients who participated in Studies I and II, underwent an overnight in-hospital 
cardiorespiratory polygraphy in the pulmonary clinic (Embla®, Medcare Flaga hf,
Medical Devices, Reykjavik, Iceland). In the PG, measurements of
electrocardiography, sleeping position, inspiratory flow pressure with nasal prongs,
abdominal and thoracic movements, and periodic leg movements were recorded.
Respiratory flow was measured with the help of a differential pressure sensor, 
connected to the nasal prongs, to detect alterations in nasal pressure. Respiratory
movements were measured with abdominal and thoracic belts with strain gauges.
Periodic leg movements were measured using electromyographic sensors connected
to the m. tibialis anterior, in both legs. In addition, transcutaneous carbon dioxide
partial pressure was measured (PTcCO2; TCM3, Radiometer A/S, Copenhagen,
Denmark).
PTcCO2 is based on measuring the diffusion of carbon dioxide through tissues
and skin with the help of a heated electrode. Arterial oxyhaemoglobin saturation 
(SaO2) was measured via a finger probe pulse oximeter (Oximeter Embla A10 XN,
Embla, Denver, Colorado USA) to determine the episodes of arterial
oxyhaemoglobin desaturation of 4% units or more per hour (oxygen desaturation 
index, ODI4). Desaturations were automatically determined from a recording using
Somnologica software.
An experienced scorer removed all possible artefacts and visually determined
hypopnoeas and apnoeas from the recording. Apnoea-hypopnoea index (AHI) was
calculated using internationally accepted criteria; the number of events expressed per
hour. Electroencephalogram was not available; therefore, respiratory effort related
arousals (RERA) were not scored. All the patients had symptoms that suggested
OSAS, but the diagnosis of obstructive sleep apnoea was only made if the AHI was
≥5 per hour. CPAP therapy was introduced to those patients whose AHI was over 15
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per hour. However, if a patient suffered from severe symptoms, CPAP therapy was
also commenced with an AHI of 5-15 per hour.
4.2.1.2 Static-Charge-Sensitive bed (Study III)
All patients who were included in Study III underwent an overnight in-hospital study
with a static-charge-sensitive bed (SCSB, Bio-Matt® Biorec, Turku, Finland) and 
simultaneous oximetry recordings (BCI-oximeter ECG-monitor, Model 3101, CAT
3101A, Waukesha, Wisconsin, USA) at baseline. This method was the most common
to diagnose SDB until the millennium. SCSB is a monitoring device, that can be used
underneath a regular foam mattress without any electrodes or probes being attached
to the patient (Alihanka et al. 1981; Polo 1992). It has a motion sensor that monitors
movements in bed via static charge layers that move with the body’s movements,
resulting in a potential difference and sensor charge modification. The potentials are
filtered, amplified, and recorded, and then categorised according to their frequencies
of three movement types: gross body movements, respiratory movements, and 
heartbeats. The set-up of SCSB can be seen in Figure 10.
The SCSB recordings were analysed visually by two independent scorers to
detect increased respiratory resistance (IRR), which is an indicator of prolonged 
partial upper airway obstruction or four types of periodic breathing patterns: P1, OP-
1, OP-2 or OP-3. The P-1 and OP-1 patterns reflect periodic breathing with moderate
or high respiratory effort, while OP-2 and OP-3 reflect the episodes of hypopnoea
and obstructive sleep apnoea (Anttalainen et al. 2016; Polo 1992). In our study,
scoring was performed according to rules valid at that time. However, afterwards
there has been discussion about the right classification of these breathing patterns
(Tenhunen et al. 2013). In order to determine their severity, these patterns were
quantified in three-minute epochs, and their frequency was expressed as a percentage
of total time in bed (TIB). If the frequency was >5 % of TIB, it was considered as 
clinically significant.
In addition, SaO2 was measured during the SCSB study. A recording was made
with a finger probe and analysed using UniPlot software (Unesta Oy, Turku,
Finland). This software reports the minimum, maximum, and median SaO2. In
addition, it reports ODI4. 
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Participants and Methods 
Figure 10. Static-charge-sensitive bed (SCSB) (Anttalainen et al. 2007). Reprinted with the 
permission of Springer Nature.
Questionnaires (Study I)
In the evening, following a standardised hospital meal, the participants completed a
battery of questionnaires. The same questionnaires were repeated after three years in
a follow-up visit. At the baseline, there were missing values for ESS (Johns 1991) in
6 patients (2.7 %), DEPS (Salokangas et al. 1995) in 7 patients (3.1 %), PSQI
(Buysse et al. 1989) in 4 patients (1.8 %), and appetite-VAS and hunger-VAS
(Parker et al. 2004) in 27 patients (12 %). At the follow-up visit, there were no
missing values in the questionnaires.
4.2.2.1 Epworth Sleepiness Scale (ESS)
Excessive daytime sleepiness was assessed using the Epworth Sleepiness Scale
(ESS) (see Appendix 1). There are eight questions in this questionnaire, and all
questions had a possible score from 0 to 3. Hence, the maximum possible score is
24. Higher points indicate a more severe tendency to doze off, and a total score >10
suggests EDS. The answers are based on feelings during the two weeks before filling
out the questionnaire.
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4.2.2.2 Depression scale (DEPS)
Depressive symptoms were evaluated using the depression scale (DEPS) (Appendix
2). The maximum score of this questionnaire is 30 points, and more points indicate
more depressive symptoms. There are 10 questions; the score for each question is 0-
3. A score higher than nine indicates possible depression. The answers need to refer
to the period of one month prior to filling out the questionnaire.
4.2.2.3 Pittsburgh Sleep Quality Index, (PSQI)
Insomnia symptoms and sleep quality were evaluated using the Pittsburgh Sleep
Quality Index (PSQI) (Appendix 3). It is a validated method used to screen sleep
disorders and quality of sleep. It has 19 questions divided into seven components.
These components include subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleeping medication, and
daytime dysfunction. The total score for the questionnaire is the sum of each
component score. Overall score range is 0 to 21, and more points indicate a worse
quality of sleep. The questionnaire only evaluates the one-month period before a 
person is completing the questionnaire.
4.2.2.4 State-Trait Anxiety Inventory, (STAI)
Anxiety was screened with the help of the State-Trait Anxiety Inventory (STAI)
(Spielberger et al. 1983) (Appendix 4). It has 40 questions in two groups, that
evaluate separately two different kinds of anxiety, i.e., state (STAI-S) and trait 
(STAI-T). State anxiety measures anxiety related to an event, and trait measures 
anxiety as a personal characteristic. In this study, STAI-S was used. The score on 
STAI-S is based on the feeling at the moment one is filling out the questionnaire,
and higher scores indicate greater feeling of anxiety. Usually, scores under 38 are
considered “no anxiety”, scores of 38-44 are considered as “moderate anxiety” and
scores over 44 are considered “high anxiety”. The maximum score on the STAI is
80 points. The scoring is different for all questions and the 4-point scale is created
from answers labelled as 1) not at all, 2) somewhat, 3) moderately so, and 4) very 
much so. The final score on the questionnaire is the sum of all these separate scores.
4.2.2.5 Visual analogue scales
Visual analogue scales (VAS) (Appendix 5) were used to assess the participants’
hunger, thirst, appetite, food quantities, and nausea. In addition, VAS scales were
used to evaluate the cravings for different food categories, which included sweet,
salty, starch, fruit, vegetables, meat/fish/egg, and dairy. Participants chose a score
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Participants and Methods 
based on their feeling at the moment when completing the VAS scale, and a higher
score indicated stronger cravings. The results of the VAS scales were reported as
millimetres (score 0-100 mm).
4.2.2.6 Exercise habits and duration
Exercise habits were asked on the questionnaires with the question “How often do
you exercise on average?” The answer alternatives were 1) not at all, 2) less 
frequently than once a week, 3) once a week, 4) twice a week, 5) three times a week,
6) four times a week, or 7) five times a week. Exercise duration was then evaluated
with the question: “How long is your exercise duration?” Alternatives were 1) 0-20 
minutes, 2) 20-40 minutes, 3) 40-60 minutes and 4) over 60 minutes. The final score
was the number that reflected the most accurate alternative. These variables were
treated as separate questions in the analysis (Appendix 6).
4.2.2.7 Medication, smoking, and alcohol consumption
Medication use by the participants was also asked on the questionnaire, and the
patients provided commercial names and daily doses of medications that they used.
Medications were then manually categorised by the Anatomic Therapeutic Chemical
Classification (ATC) system, a drug classification system developed by the World
Health Organization Collaborating Centre for Drug Statistics Methodology in
Norway. In ATC, medicines are divided into groups according to the organ or system 
on which they act and their therapeutic, pharmacological and chemical properties
(Chen et al. 2012).
Smoking was asked with the question: “Have you ever smoked 6 months or more
during your life?". Choices were 1) yes or 2) no and the patients were categorised as
smokers or non-smokers based on answer to this question. Alcohol consumption was
categorised as 1) not at all 2) 1-6 alcohol doses per week, 3) 7-14 alcohol doses per
week or 4) 15-24 alcohol doses per week. A single dose was defined as one beer
(0.33 l) or 12 cl of wine or 4 cl of strong alcohol (alcohol percentage >35 %). The
final score was the number, that reflected the person’s consumption most accurately 
(Appendix 6).
Blood samples (Study II)
Venous blood was drawn in the morning, after an overnight fast, to measure leptin 
and IGF-1 concentrations. All blood samples were stored in ice and centrifuged
immediately, and then kept frozen at -70 ◦C until analysed. Leptin was assayed using
the ELISA method and IGF-1 with immunoluminometric assay (DRG Instruments
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GmbH®, Marburg, Germany). The reference ranges for leptin concentrations were
7.36 ± 3.73 ng/ml for women and 3.84 ± 1.79 ng/ml for men. The inter-assay
coefficient of variation was 11.55 % and the control sample level 1.0 ng/ml. 
Reference ranges for the IGF-1 concentrations are presented in Table 5. Both
baseline and follow-up leptin and IGF-1 concentrations were available from 114
patients, and 49 of these (43.0%; 29 men, 20 women) were categorised as CPAP
users, and 60 as non-users (52.6%; 33 men, 27 women ) as presented in Figure 8. 
For five of these patients, information on CPAP use was not found (4.4%; 3 men, 2 
women). The data for the average hours of CPAP use were derived from 48 patients
(29 men, 19 women).
Table 5. Reference range values for IGF-1 concentrations.
Age (years) Reference range (nmol/l)
21–30 27–107
31–50 14–36
51–70 6–27
>70 8–23
Medication data (Study III)
To investigate the effect of CPAP therapy on medicine use, the data for medication
use as daily defined doses (DDD) were collected from the National Social Insurance
Institution. It maintains the reimbursement registry in Finland, for the medicines
prescribed for chronic illnesses. All Finnish citizens are entitled to reimbursements
if they meet the requirements, which are stricter than criteria needed for a diagnosis.
Patients need a separate application and a statement from the doctor for this
reimbursement. The registry has been available from year 1993 forward. In the
database, medicines are categorised according to diagnosis. The data were collected
on the following nine disease categories: Diabetes (both Type 1 and Type 2),
hypothyroidism, severe psychosis and other severe psychiatric diseases, chronic
heart failure, connective tissue diseases, chronic obstructive pulmonary disease
(COPD) and asthma, hypertension, arteriosclerosis, and cardiac arrhythmias.
To compare the medicine use of participants to the medicine use of the entire
Finnish female population from years 1993 to 2001 and medication data on the same
disease categories as described above, were derived from the National Social
Insurance Institution for women.
The DDD of medications for each above-mentioned category were collected for
each patient. Medication data were retrieved three years prior and three years after
the CPAP therapy was commenced or the sleep study was performed. Medication
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data were available for 323 participants. Since the medication data from the National
Social Insurance Institution was available from 1993–2001, only patients who had 
their sleep recordings gathered between 1996 and 1998 were included. Thus, the
final study population included 182 patients (66 CPAP users and 116 controls) as 
presented in Figure 9.
Comorbidity (Study III)
Overall comorbidity before CPAP therapy initiation was evaluated using the data for
the same categories as previously mentioned. These data were collected one year
before the CPAP therapy was commenced. If the patient had purchased medicines
that were included in one of the categories at least once, that patient was considered
to have the specific disease. The patients were then categorised into having one, two
or three comorbidities. There were no patients with more than three comorbidities.
CPAP users and controls were evaluated separately.
Statistical Analyses
4.2.6.1 Study I
In the first study, which screened the data on questionnaires and weight, the data are
presented as median with range. The associations, except for regression analysis,
between the variables were analysed using SAS (Statistical software package for
Windows 9.2). Correlations between the variables were evaluated with Spearman’s
rank correlation coefficients because of the distribution of the data. The differences
between CPAP-users and non-users were evaluated with the Wilcoxon Two-Sample
Test, where a p-value less than 0.05 was considered statistically significant. All the
variables that differed between the CPAP users and non-users, were included in the
further regression analysis for finding factors influencing on the change in BMI. 
Analysis of variance (ANOVA) was used to test with-in or between group variation 
and an ordinary least squares linear regression model was fitted. Results were
presented as standardized beta estimates and 95 % confidence intervals (CI) and a p-
value ≤0.05 was considered statistically significant. The analyses were performed
separately for males and females and for both regarding CPAP use. Regression
analysis were performed with IBM SPSS version 25 (IBM Corp. Released 2017.IBM
SPSS Statistics for Windows, Version 25.0. Armonk, NY:IBM Corp.)
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4.2.6.2 Study II
In the second study, which evaluated the effect of CPAP therapy on leptin and IGF-
concentrations, the data are presented as a median with an interquartile range or as a
mean with a range. The limit of quantitation was 1.00 ng/ml in leptin, and 3.25 nmol/l
in IGF-1. Therefore, leptin concentrations <1.00 ng/ml were imputed with 0.50
ng/ml, and IGF-1<3.25 ng/ml with the value of 1.63 ng/ml.
Statistical analyses were performed using IBM SPSS version 23 (IBM Corp.
Released in 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY:
IBM Corp). To study the effect of covariates on a three-year change in leptin
concentrations, an ordinary least squares linear regression model was fitted,
separately for both genders. Conditional inference trees were used to find and
visualise statistically significant interactions between the categorical covariates.
Bipartite correlations between the variables were studied using Spearman's rank
correlation coefficients. To compare the groups, Mann–Whitney U test was used for
the continuous variables and a chi-squared test was used for the categorical variables.
P-values less than 0.05 were considered to be statistically significant.
4.2.6.3 Study III
In Study III, differences between the CPAP users and controls were compared in
age, BMI, and neck circumference by using the two-sample T-test. Chi-squared test
was used to test the differences in smoking and the proportions of SDB patterns.
Wilcoxon Signed Rank test was performed to evaluate changes in DDD of
medications within CPAP and control groups, and the differences in the changes
between groups with Mann-Whitney U-test. In addition, the comorbidities were
evaluated with Mann-Whitney U-test. The correlations between the medication use
and BMI were evaluated with Spearman´s rank correlation coefficient. Level of
significance was set at <0.05. Statistical analyses were performed using the SAS 9.4
System for Windows (SAS Institute Inc., Cary, NC) and the data were expressed as
mean ± standard deviation.
4.3 Designs of the studies
Studies I and II were prospective observational follow-up studies in a clinical
population of suspected SDB that were referred to Turku University Hospital,
Department of Pulmonary Diseases. Study III was a retrospective registry study, that
used clinical cohort of 601 consecutive females with suspected SDB derived from
the database for the Department of Pulmonary Diseases at Turku University 
Hospital. 
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4.4 Ethical aspects
In Studies I and II, the study protocol was approved by the Ethics Committee of the
Hospital District of Southwest Finland, in Turku, Finland. All patients gave their
written informed consent. In Study III, the study protocol was approved by the Joint
Commission on Ethics of Turku University and Turku University Hospital, and the
National Agency for Medicines. The study was a registry study, and all aspects of
the registry were conducted according to the principles of Good Clinical Practice and 
in accordance with the Declaration of Helsinki. 
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5 RESULTS
5.1 Effects of CPAP
Weight
Change of weight was evaluated with the help of BMI. In all three studies, CPAP 
users had more obesity at the baseline compared to the controls (Table 6). The
change in BMI during follow-up did not differ in Study I or Study II between CPAP
users and the controls. In Study III, a change in BMI did not differ between the
groups, and it had no effect on the medicine use.
Table 6. BMI (kg/m2) in all study populations at baseline.
CPAP users Controls p-value
Females n, % Median Range Median Range
Study I 122 (54.7) 34.7 23.3–56.5 28.2. 21.5–55.2 <0.001
Study II 49 (43) 33.7. 30.1–37.1 28.3 26.2–33.7 <0.001
Study III 188 (100) 36.5 34.5–38.5 31.4 30.1–32.7 <0.001
In addition, a waist hip ratio (WHR) was available from 41 patients (25 females and
16 men). At baseline, WHR did not differ between CPAP users and non-users when
gender was considered. At follow-up, female CPAP users had higher WHR than non-
users and male CPAP users had lower WHR than non-users. In both genders, the
change in WHR did not differ between CPAP users and non-users (Table 7).
Table 7. Waist hip ratios of the patients and their differences.
Female Male
CPAP (n=10) Controls (n=15) CPAP (n=7) Controls (n=9)
Mean SD Mean SD p-value Mean SD Mean SD p-value
Baseline 1.0 0.06 0.97 0.060 0.181 0.89 0.086 0.90 0.047 0.632
Follow-up 0.97 0.088 0.92 0.077 0.016 0.99 0.066 1.17 1.416 0.013
Change 0.02 0.089 -0.05 0.090 0.065 0.10 0.100 0.04 0.084 0.172
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Results
In Study I, weight gain in the CPAP group was not associated with baseline 
severity of OSAS, depressive symptoms, sleep quality, anxiety, exercise habits or
duration, or a craving for distinct food categories or food quantity. However,
gaining weight was associated with a feeling of satiety after a full meal (r= 0.36,
p=0.010) (Table 8) at the baseline for patients using CPAP. Moreover, weight gain
was associated with a higher use of CPAP (r=0.28 p=0.015) and a craving for less 
sweets (r= -0.34, p=0.011) at the three-year follow-up. In addition, in Study II,
weight gain was associated with higher compliance with CPAP use (r= 0.29, 
p=0.046), but not when males (r=0.14, p= 0.464) and females (r=0.31, p=0.194)
were evaluated separately.
Table 8. Correlations between the baseline variables and change in BMI in study I.
CPAP users n=76 Non-users n=73
AHI (#/h)
ODI4 (#/h)
DEPS (0–30)
ESS (0–20)
PSQI (0–21)
Fruit VAS (0–100)
Protein VAS (0–100)
Dairy products VAS (0–100)
Salty VAS (0–100)
Sweet VAS (0–100)
High carbohydrate
products VAS (0–100)
Vegetables VAS (0–100)
Thirst VAS (0–100)
Satiety VAS (0–100)
Hunger VAS (0–100)
Nausea VAS (0–100)
Appetite VAS (0–100)
Food quantity VAS (0–100)
Exercise habits (0–7)
Exercise duration (0–7)
r
−0.133
−0.017
0.149
−0.005
−0.078
−0.040
0.005
−0.038
−0.203
−0.202
−0.208
−0.065
0.070
0.359
−0.069
0.115
−0.057
−0.107
0.176
−0.157
p-value
0.353
0.904
0.281
0.970
0.572
0.788
0.976
0.797
0.161
0.174
0.156
0.662
0.627
0.010
0.632
0.427
0.692
0.458
0.203
0.266
r
−0.210
−0.056
0.191
−0.160
0.110
0.128
0.041
−0.035
0.080
0.006
0.048
−0.058
0.232
−0.014
0.056
−0.223
0.028
0.137
0.020
0.139
p-value
0.080
0.646
0.119
0.192
0.356
0.317
0.750
0.786
0.534
0.961
0.706
0.656
0.062
0.910
0.660
0.075
0.825
0.278
0.872
0.259
Values are presented as median (range). BMI body mass index (kg/m2), AHI apnoea-hypopnoea
index (events per hour), ODI4 Oxygen desaturation index with the desaturation of 4% or more,
DEPS depression scale (score), ESS Epworth sleepiness scale (score), PSQI Pittsburgh Sleep 
Quality Index (score), VAS visual analogue scale (millimetres).
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In the regression analysis, there were no other predictors of weight gain than the
sufficient use of CPAP, a higher baseline BMI, or higher depressive symptoms at the
baseline. When CPAP users and non-users were analysed separately, the baseline 
BMI remained a predictor of weight gain in all groups, whereas baseline DEPS
remained a predictor in all but those men who were using CPAP and those women
who were not using CPAP (Table 9).
Table 9. Regression analysis of factors influencing weight gain during three years of follow-up
Baseline Baseline
BMI (kg/m2) DEPS
β CI 95 % p-value β CI 95 % p-value
All 0.84 0.71–0.98 <.001 0.167 0.03–0.33 0.017
CPAP-users (n=76) 0.83 0.69–0.99 <.001 0.20 0.05–0.38 0.01 
Male (n= 32) 0.94 0.55–0.92 <.001 0.11 – 0.16–0.38 0.40 
Female (n=44) 0.94 0.77–1.3 <.001 0.26 0.07–0.47 0.01 
Non-users (n=73) 0.90 0.77–0.95 <.001 0.16 0.04–0.28 0.09 
Male (n=33) 0.88 0.65–0.95 <.001 0.30 0.08–0.53 0.01 
Female (n=40) 0.98 0.88–1.1 <.001 0.05 -0.1–0.1 0.93 
Mood
CPAP users had more depressive symptoms at baseline than the controls did
(p=0.011), and their symptoms were alleviated more during the follow-up period,
than for the controls (-3 vs. 0 points, p=0.002) (Figure 11).
Anxiety symptoms did not differ between the study groups at the baseline (35 in 
the CPAP group vs. 32.5 points in the controls, p= 0.054), but at the follow-up, these
symptoms had alleviated more in the CPAP group (-3 points in the CPAP group vs.
only by 1 in the controls, p<0.001.) (Figure 11).
Sleepiness did not differ between the groups at baseline (10 points for the CPAP
users and 9 for the controls, p=0.572), but sleepiness was alleviated more in the
CPAP group during the follow-up time (-3.5 points vs. -2 points, p=0.031) (Figure
12).
Sleep quality was the same at the baseline among the CPAP users and the
controls (7 points vs. 6 points, p=0.06), but during the follow-up time, sleep quality
improved more in the CPAP group (-1 points vs. 0 points, p<0.001) (Figure 12).
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Figure 11. Change in DEPS (depressive symptoms) and STAI-S (state anxiety) scores. Higher
scores in DEPS indicate higher amount of depressive symptoms and higher score in
STAI-S indicate more anxiety.
Sleepiness, p=0.031 Sleep Quality, p<0.001 
12 7,5 
ES
S 
Sc
or
e 
10 
8 
PS
Q
I S
co
re
 
7 
6 6,5 
4 
2 
6 
0 5,5 
Baseline Follow-up Baseline Follow-up 
Time Time 
CPAP users Controls CPAP users Controls 
Figure 12. Change in ESS (sleepiness) and PSQI (sleep quality) score. In ESS, higher score indicates
higher tendency of falling asleep. In PSQI, higher score indicates worse sleep quality.
Lifestyle
Exercise habits (p=0.412) or duration of exercise (p=0.712) did not differ between
CPAP users and non-users at the baseline. At follow-up, neither absolute numbers,
nor a change in the number of exercise sessions per week differed (p=0.230 for
change in scores in exercise habits and p=0.484 in exercise duration).
Cravings for different food categories, satiety, hunger, and food quantity did not
differ between the groups at baseline. However, the feeling of thirst was higher in 
CPAP users. At the follow-up, the control’s thirst increased, whereas CPAP group
thirst did not change as shown in Table 10.
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Table 10. Lifestyle during the study and differences between the groups.
Baseline Follow-up Change
CPAP users Non-users CPAP users Non-users CPAP users Non-users
p-valueMedian Range Median Range p-value Median Range Median Range p-value Median Range Median Range
Fruit VAS
(0–100)
77 0–100 81.5 1–100 0.783 80 14–100 78 0–100 0.422 1.5 47–88 0 -95–57 0.255
Protein VAS 
(0–100)
77 0–100 67.5 0–100 0.420 81 8–100 81 0–100 0.260 –9 -85–40 -1 -59–96 0.077
Dairy products
VAS (0–100)
68 0–100 60 1–100 0.783 75 3–100 76 0–100 0.812 8 -79–90 0 -78–93 0.312
Salty VAS 
(0–100)
26.5 0–100 23 0–100 0.286 18 0–100 32 0–98 0.195 –3 -92–63 0 -85–88 0.063
Sweet VAS 
(0–100)
40 0–100 53 0–100 0.286 37 0–100 50 0–100 0.281 –1 -72–98 0 -96–82 0.910
High– 57 0–100 23 0–100 0.906 70 1–100 73 0–100 0.734 1 -66–99 -3.5 -128– 0.137
carbohydrate 
products
VAS (0–100)
101
Vegetables VAS
(0–100)
62 0–100 68 0–100 0.683 76 0–100 79 0–100 0.930 9 -21–94 1 -43–89 0.090
Thirst VAS 25 0–100 15 0–97 0.032 32 0–100 25 0–100 0.774 0 -98–91 7.5 -65– 0.026
(0–100) 100
Satiety VAS 73 0–100 77.5 10– 0.082 33 0–100 26 0–100 0.622 –38 -100– -41.5 -100– 0.280
(0–100) 100 97 33 
Hunger VAS 6 0–100 4 0–72 0.304 15 0–100 26 0–100 0.392 3 -72–99 8.5 -41– 0.112
(0–100) 100
Nausea VAS 
(0–100)
5 0–73 5 0–65 0.812 5 0–97 5 0–66 0.590 -1 -71–89 0 -45–64 0.112
Appetite VAS 
(0–100)
8 0–100 7 0–69 0.310 24 0–100 23 0–99 0.538 5.5 -56–99 10 -59–98 0.387
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Baseline Follow-up Change
CPAP users Non-users CPAP users Non-users CPAP users Non-users
p-valueMedian Range Median Range p-value Median Range Median Range p-value Median Range Median Range
Food quantity
(VAS 0–100)
13.5 0–99 10 0–100 0.422 27 0–90 29 0–98 0.147 4 -11–68 13 -71–95 0.154
Exercise habits 4 1–7 4 1–7 0.412 4 1–7 5 1–7 0.557 0 -5–3 0 -3–4 0.230
(0–7)
Exercise 3 1–4 2 1–4 0.712 2 1–4 3 1–4 0.273 0 -3–2 0 -2–2 0.484
duration (0–7)
VAS visual analogue scale (millimetres).
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5.2 Leptin and IGF-1 concentrations
Leptin concentrations did not differ at baseline between CPAP users and non-users
(17.25 ng/ml vs. 16.7 ng/ml, p=0.870). However, there was a difference in absolute
leptin concentrations at the follow-up (26.95 ng/ml vs. 8.60 ng/ml, p=0.002) as well
as change in leptin concentrations (9.13 ng/ml vs. -5.86 ng/ml, p=0.007), regardless
of age or BMI. When the change in BMI was also considered, CPAP use was still a
significant factor for change in the leptin concentrations. An increase in BMI by 1
kg/m2 was associated with an increase of 2.1 ng/ml (p=0.047, 95% CI 0.03 to 4.2), 
and CPAP use was associated with an increase of 13.0 ng/ml (p=0.017, 95% CI 2.4
to 23.6) in leptin concentrations (Figure 13).
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4 Figure 13. Effect of CPAP and 
BMI in leptin concentrations. 
2 When BMI increased by 1 
kg/m2, leptin concentrations 
0 increased by 2.1 ng/ml. Using 
BMI CPAPCPAP  increased leptin use concentrations by 13.0 ng/ml
Surprisingly, when WHR was considered, in female CPAP users, when WHR
elevated, their leptin concentrations decreased. However, this analysis must be
interpreted with caution due to small subgroups (Table 11). The subgroups did not
have sufficient statistical power for further analysis.
Table 11. Correlations between the change in leptin concentrations and change in waist hip ratio.
r p-value
Female (n=25)
CPAP users -0.60 0.07
Non-users -0.05 0.85
Male (n=16)
CPAP users 0.57 0.18
Non-users -0.43 0.24
60
 
  
  
   
     
 
 
    
 
     
 
    
        
   
  
  
  
 
    
 
   
    
   
5.2.1 
gender: Male gender: Female 
60 60 P = 0.018 
-r-
50 50 
E E --... --... ,s 40 ,S 40 
C C ·t t 
~ 30 P = 0.123 ~ JO 
C C 
"' "' 24.3 Q) Q) 
2 20 2 20 22.7 
10 10 
0 0 
Baseline Follow-up Baseline Follow-up 
Results
Baseline IGF-1 concentrations did not differ between CPAP users and the controls 
(13.6 nmol/l vs.11.8 nmol/l, p=0.594), nor did it differ at follow-up (15.6 nmol/l
vs.15.7 nmol/l, p=0.933), or change during the follow-up period (2.6 nmol/l vs. 3.2
nmol/l, p=0.775).
In addition, fasting blood glucose and thyroid stimulating hormone (TSH) was
measured, but these were not included in this analysis. There were 27 patients who
had diagnosed diabetes, and 21 patients had diagnosis for hypothyroidism.
Effect of gender on leptin concentrations
When men and women were assessed separately, there were no differences at
baseline (median male 12.4 ng/ml vs. median female 18.0 ng/ml, p=0.578) in the
leptin concentrations. However, at the follow-up, women had higher leptin 
concentrations than did the men (median 32.4 ng/ml vs. median 7.2 ng/ml p<0.001).
In women, the median change in leptin concentration among the CPAP users was
25.97 ng/ml, and was 4.97 ng/ml among the non-users (p=0.010), whereas in men,
the change did not differ between the CPAP users and non-users (-0.94 ng/ml vs. -
8.88 ng/ml; p=0.087) (Figure 14).
Figure 14. Leptin concentrations at baseline and at follow-up and differences between the genders 
according to CPAP use. Reprinted from original article II, with permission of Sleep and 
Breathing.
5.3 Medication use in females
There was no difference at the baseline between the female groups in terms of age,
neck circumference, or smoking. The CPAP group had a greater BMI and more 
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illnesses than the controls did (Figure 15). Both groups had the same proportion of
patients with prolonged partial upper airway obstruction and the classic form of sleep
apnoea. At baseline, overall medication use was higher in the CPAP users than it 
was in the controls (p= 0.036).
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Figure 15. The number of comorbidities at baseline and the differences between the female CPAP 
users and controls (p= 0.017).
During the three years after CPAP initiation (CPAP users) or a diagnostic sleep study
(the control group), the change in medication use did not differ (p=0.054). However,
at the three-year follow-up point, the medication use was higher in CPAP users than
in the controls (p<0.001). There was no difference in medicine use either in baseline,
or in follow-up, or change in use when the type of SDB (prolonged upper airway
obstruction or classic form of sleep apnoea) was considered (p=0.582). Medicine 
use for COPD and asthma increased during the three-year follow-up in both groups,
but the rise was higher in the CPAP group (mean 203.71 vs. 113.14; p=0.048). The
use of medicine for severe mental illnesses, such as psychosis, increased slightly in
the CPAP group, whereas in the control group the use decreased (25.9 vs -23.41;
p=0.046). There was no significant change in medication use either for diabetes,
hypothyroidism, chronic heart failure, connective tissue diseases, hypertension,
arteriosclerosis, or cardiac arrhythmias (Figure 16).
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Figure 16. Change in medication use presented as defined daily dose (DDD) values, and the
differences between females using CPAP and control group *p=0.048, **p=0.046. 
Modified from the original publication III.
In CPAP users, only the medication use for asthma and COPD increased (Table 
12), and a similar increase was also found in the entire population of Finnish
females. The increase in medicine use among the CPAP users in all other
categories, except for the decrease in arteriosclerosis and cardiac arrhythmias 
demonstrated a similar trend compared to the entire Finnish female population,
although it did not reach statistical significance. In the Finnish female population,
between years 1993 and 2001, medication use increased in all categories. The
controls demonstrated a decreasing, but still statistically non-significant, trend in
medication for severe mental illnesses, chronic heart failure, arteriosclerosis, and
cardiac arrhythmias.
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Table 12. Use of medication in defined daily dose (DDD) in female CPAP users reprinted from 
original publication III with permission from Respiratory Medicine.
CPAP group (n=66)
Diabetes
Hypothyroidism
Severe mental
illnesses 
Heart failure
Connective tissue 
diseases
Asthma and COPD
Hypertension
Arteriosclerosis 
Before
Mean
53.5 
56.6 
13.4 
25.1 
10.5 
361.6
751.7
76.8 
SD
296.7
216
98.1 
204.1
83.6
1090.3
1129.9
347.5
Follow-up
Mean SD
104.2 403.9
89.9 306.4
39.3 300.9
38.3 219.4
21.2 171.9
565.3 1061.6
875.5 1327.5
63.1 272.8
Change
Mean
50.7 
33.3 
25.9 
13.1 
10.7 
203.7
123.8
-13.7 
SD
263.8
211.5
203.0
94.0 
88.4 
614.8
753.4
81.4 
p-value
0.188
0.313
0.5
0.5
1
0.002
0.111
0.313
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6 DISCUSSION
In recent years, the research into sleep apnoea has turned toward phenotyping 
patients and finding “treatable traits”, such as we find in asthma. As the 
understanding has grown, the need for more precise research and study protocols has
been needed. Phenotyping this large sector of people needs more dynamic and
innovative studies and large amounts of research data in order to reveal the true
phenotypes of SDB. Not all future phenotypes of SDB are candidates for solely
CPAP therapy; therefore, the knowledge of the effects of long-term CPAP therapy
is welcomed. This current study has concentrated on the effects of long-term CPAP
therapy in order to screen those factors that influence the outcomes of SDB
treatment. Women were of special interest, as most of the previous studies have
consisted of mainly men. 
This study can be divided into two different parts. The first part concentrates on
the effect of CPAP therapy on SDB symptoms, weight, and factors that influence
weight during therapy. The second part concentrates on female comorbidities,
medication use, and the effect of SDB type on both. All of these efforts, however,
are targeting the same goal, namely, to determine the benefits and non-benefits of
long-term CPAP therapy in order to help in evaluation of the right patients who will
benefit the most from CPAP therapy.
6.1 Weight
In 1981, when Dr Sullivan and his co-workers invented the CPAP machine (Sullivan
et al. 1981), the assumption was that treating SDB would lead to weight reduction,
and that outcome was thought to be true until the late 1990’s (Loube et al. 1997). 
Since then, the knowledge has increased and today the consensus is that
unfortunately CPAP therapy does not lead to weight reduction (Drager et al. 2015;
Myllylä et al. 2016; Ou et al. 2019). The mechanisms behind this are probably
multifactorial, including the toning down of sympathetic overdrive, the reduction of
energy expenditure, and changes in hormonal secretion (Drager et al. 2015).
In Studies I and II, weight gain among patients was associated with a higher
compliance with CPAP, and more depressive symptoms and higher BMI at the
beginning of the study. The association between CPAP use and weight gain could
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be explained by the factors noted previously, such as toning down of sympathetic
overdrive, and it is in line with the previous studies (Drager et al. 2015). In the
regression analysis, when users and non-users were analysed separately, the results 
of having more depressive symptoms at the baseline, and higher baseline BMI
influencing weight gain, remained constant among the CPAP users. More depressive
symptoms at the beginning can be associated with the fact, that these patients could
have had a habit of alleviating their psychological stress with eating, and that habit 
remained, even when the SDB was treated. Moreover, patients with more depressive
symptoms could have had a clinical depression revealed behind the depressive
symptoms that related to SDB, and during the three-year follow-up, the
antidepressant medication was initiated, often associated with weight gain. 
The increase in the use of antidepressant medication has been suggested as being
one contributor to the rising number of people with obesity. However, in our study 
population we could only evaluate the amount of medications used for severe
psychiatric disorders, which excluded milder depression, and therefore we could not
evaluate this aspect sufficiently enough (Gafoor et al. 2018). Baseline BMI being
higher at the beginning can simply imply that these patients ate more or ate more
unhealthy food to begin with, making it more difficult for them to lose weight, as no
lifestyle intervention, such as weight loss support, was included in this study. In
previous studies it has been shown, that CPAP alone does not lead to positive
lifestyle changes (Bamberga et al. 2015; Chirinos et al. 2014). Of note, craving less
sweets at the three-year follow-up was associated with weight gain when using
CPAP. This association could be due to methodological factors, as in the regression
analysis the association between the craving less sweets and weight gain
disappeared.
Contrary to our expectations, weight gain was not associated with craving more
sweets or high-carbohydrate foods. Unfortunately, our questionnaires were
introduced to patients right after having a full meal, which could explain the absence
of any cravings, and the unexpected association of their craving fewer sweets. In
addition, the severity of SDB was not associated with weight gain. This finding is in
line with the previous studies (Myllylä et al. 2016). Moreover, weight gain in the
CPAP group was not associated with exercise habits or their duration, the craving 
for distinct food categories, or any food quantity. As mentioned earlier, lifestyle
changes in SDB patients leading to weight loss are rare if additional support is not
provided.
Even though we used an extensive array of questionnaires along with
cardiorespiratory polygraphy, we were unable to determine the factors or establish
any markers, that predicted the weight changes in SDB patients using CPAP therapy.
However, our study still reinforces the association between the CPAP therapy and
weight gain if no additional support is provided.
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Discussion
6.2 Mood 
Our study showed that in patients with SDB, depressive symptoms and anxiety were
alleviated, as expected (Gupta & Simpson 2015) during CPAP therapy.
SDB and depressive disorder have a strong association, and the symptoms also
overlap (Hobzova et al. 2017). It has been suggested that 35 % of patients with OSA 
have depressive symptoms (Garbarino et al. 2018a) and that women with OSAS have
more depressive symptoms than men (Pillar & Lavie, 1998). Our Study I, which
investigated the association of CPAP and mood, was gender balanced as it had 46 % 
women. Depressive symptoms overlapping with SDB can lead to a situation when
treating SDB with CPAP can reveal underlying clinical depression. In our study, part
of the depressive symptoms at the baseline could have been secondary to the
untreated SDB, whereas the residual depressive symptoms could have been a sign of
“true” depression.
Previous studies have offered diverse results on the effect of CPAP therapy on
depressive symptoms, especially during long-term therapy (Hobzova et al. 2017). 
There are studies that suggest that CPAP therapy alleviates depressive symptoms
(Sánchez et al. 2001) while others have had no effect (Muñoz et al. 2000). In our
study population, 56.6 % of CPAP users had over 9 points in DEPS questionnaire
before CPAP initiation, suggesting clinical depression. Among the non-users, 34.2
% had clinical depression according to DEPS. In the follow-up, 22.4 % of CPAP
users and 35.6 % of non-users had over 9 points, indicating a reduction of depressive
symptoms if CPAP was used. However, there was no significant correlation between
the hours of use and DEPS score. It is unlikely that the reduction of depressive
symptoms observed in our study was due to a placebo-response, as has been the case
in some other studies (Yu et al. 1999), because our follow-up time was three years
and the use of CPAP was controlled and was of sufficient length.
Anxiety is a common symptom in OSAS, and its prevalence is reported to be as
high as 53.9 % (Rezaeitalab et al. 2014). The knowledge of the effect of CPAP
therapy on anxiety remained scarce until recently, but the interest has risen as SDB
has become more common and anxiety now recognized as a common symptom,
especially among women. However, the results are controversial. Our results are in
line with an earlier study, in which CPAP therapy alleviated anxiety particularly in
women (Campos-Rodriguez et al. 2016). Yet recently, a systematic meta-analysis of
20 randomised trials estimated that CPAP had no effect on anxiety (Zheng et al.
2019). In our study, the level of anxiety was similar at the baseline among the CPAP
users and the controls, but after the three-year follow-up, the scores on the anxiety 
questionnaire had decreased for CPAP users and increased for non-users.
The median scores in both groups did not reach the level of clinical anxiety;
therefore, these scores illustrate a trend in symptoms rather than noting anxiety as a 
disease. Since the sleep studies were not repeated, we were not able to assess if there
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were changes in SDB during the three years, and whether the worsening of symptoms
was associated with SDB. Moreover, in patients with more anxiety symptoms at
follow-up, their anxiety symptoms might initially not have been related to SDB but
rather could contribute to the discontinuation of CPAP therapy. The questionnaire used
to assess the effect of CPAP therapy on anxiety is a standardised tool, used to screen
the corresponding disease. The STAI questionnaire has two parts, and the STAI-S 
questionnaire used is validated for screening especially the state anxiety, which
illustrates a tendency to react to uncomfortable situation with anxiety, also the case in
the anxiety associated with CPAP therapy. In studies assessing anxiety and SDB, other
questionnaires have also been used, such as Hospital Anxiety and Depression Scale
(HADS), which has seven questions for assessing anxiety. The STAI-S questionnaire
was chosen as a more precise questionnaire, focusing only on anxiety. 
6.3 Lifestyle 
The most detrimental symptoms of SDB, namely, sleepiness and poor sleep quality,
improved among CPAP users in our study, a result in line with previous studies. In
one meta-analysis, CPAP therapy alleviated sleepiness in patients with OSA in a
diverse range of populations (Patel et al. 2003). Most of the previous studies have
included mainly men, but in our study, the gender differences did not stand out. It
has been previously shown that women report EDS as a SDB symptom more
frequently than men do (Rezaeitalab et al. 2014), and in one study, 12 weeks of
CPAP therapy reduced self-reported sleepiness in women (Campos-Rodriguez et al.
2016). Our study is in line with these previous findings.
Exercise habits, exercise duration, or cravings for different food categories did
not differ at baseline between the groups, nor did these behaviours change during the
follow-up. These findings are in line with previous results indicating that CPAP 
therapy alone does not result in a more active lifestyle or a more sensible diet. No
changes in consumption of total calories, protein, carbohydrate, or fat were found in
a study that followed patients with CPAP therapy for four months. There was a
modest increase in recreational activity in women, but otherwise there were no
changes in the activity patterns (Batool-Anwar et al. 2014). Physical activity was 
asked with two simple questions in our study. This is not, however, objective
evaluation, but a subjective assessment, and there is always a chance that patients 
over- or underestimate their physical activity levels or do not notice the change in it.
Actigraphy would have measured objectively the activity levels in different times of
day and revealed day-to-day variation and would have given us a more precise 
picture of patients’ activity levels. However, in previous studies, the results are in
line with ours, suggesting that activity levels do not increase with CPAP therapy,
even measured with actigraphy (West et al. 2009).
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6.4 Leptin and IGF-1
In Study II, our finding was contrary to most of the previous studies that have
suggested that leptin concentrations decrease, or remain unchanged, when OSAS
patients are treated with CPAP (Shechter 2016). However, most of these studies had
a shorter follow-up period and they also mostly consisted of men; hence the evidence
in concentrations in long-term use remains low (Zhang et al. 2014). The only two 
randomised placebo-controlled trials reported no change, nor any differences in
leptin concentrations between the CPAP-treated and the placebo groups during 2-3 
months of therapy (Hoyos et al. 2012; Kritikou et al. 2014). The proportion of female
patients in previous studies are low making our current study essential for implying
the gender-specific difference in leptin levels during long-term CPAP therapy.
The major finding was that in female patients with OSAS, three years of CPAP 
therapy were associated with increased leptin concentrations compared to both non-
users and men. Leptin concentrations increased autonomously for age or BMI. There
was also a correlation between leptin increase and gender, as leptin increased in all
females, but significantly more in female CPAP users. Alternatively, in men, leptin
concentrations decreased regardless of CPAP use. Moreover, in men using CPAP,
the leptin concentrations did not decrease as much as they did in the controls.
Women are known to have higher leptin concentrations than men have (Thomas
et al. 2000). However, in our study population, the leptin concentrations at baseline
did not differ between the genders. In one previous study, OSAS severity was related
to higher leptin concentrations in women, but not in men (Akilli et al. 2014), and in
addition, OSA patients were shown to have increased leptin concentrations when 
compared to age and BMI matched controls (Phillips et al. 2000). Moreover, obese
patients usually develop leptin resistance that results in increased venous leptin
concentrations (Zhang & Scarpace 2006), and the majority of our patients were
obese. These factors could, at least in part, explain the lack of gender differences in
leptin concentrations at our study baseline.
Previously, it has been suggested that CPAP therapy decreases leptin
concentrations (Pan & Kastin 2014), but overall these results are controversial
(Zhang et al. 2014). One study concluded that leptin concentrations decrease only if 
the CPAP treatment is effective, and poor adherence was associated with increased
leptin concentrations (Sanner et al. 2004). Our study population did, indeed, use
CPAP therapy efficiently. The hours of use were controlled once every year with
built-in clocks, and the median usage was a sufficient six hours per night. However,
we neither controlled for the residual AHI, nor repeated the polygraphy, in order to 
control the effectiveness of the therapy. Thus, the possibility of ineffective therapy 
pressure cannot be comprehensively ruled out. Nevertheless, the symptoms of SDB
were alleviated during treatment, suggesting that the therapy was, in fact, effective.
Short sleep duration is linked with decreased leptin concentrations (Taheri et al.
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2004), and when SDB is treated, sleep duration and leptin concentrations may
increase. However, in our study population, self-reported sleep duration did not
change during follow-up. In addition, leptin has a circadian rhythm, and sleep timing
might change due to CPAP treatment, thus affecting leptin’s diurnal zenith and nadir
times (Schoeller et al. 1997). Yet, the sleep timing did not change among our
patients, based on their self-reported sleep timings.
The best explanation for elevated leptin concentration is the leptin resistance that
develops with obesity. Perhaps the reduction in energy expenditure, due to toning 
down the nocturnal sympathetic overdrive, results in decreased energy consumption,
accumulation of adipose tissue, and finally elevated leptin concentrations. Women
have more adipose tissue, which could explain the differences between the genders
after treatment, one that perhaps approaches the normal variation between the
genders.
Leptin is known to have a correlation with visceral fat. Therefore, it has been
discussed whether BMI is the right measurement for weight changes when
specifically, visceral adipose tissue is controlled. In our study, we had only few 
patients with measurements of waist and hip circumference, therefore definite
conclusions could not be drawn. Our results suggest, that when WHR is increased,
the leptin concentrations decrease. However, we have a strong presentation of
females in our study population, and in sub analysis 64 % were females, and they
tend to have their adipose tissue distributed more in the hip area. Therefore, if our
study population females tended to have lost more adipose tissue from the hips than 
from the waist, WHR was elevated and thus, inaccurately suggesting gain of adipose
tissue if only WHR is included.
In our study population, IGF-1 concentrations did not change in either group
during the three-year follow-up. The effect of CPAP therapy on IGF-1 
concentrations in patients with OSAS remains controversial (Chen et al. 2015). In 
one study, it was reported that IGF-1 concentrations are increased in males ages 40-
60 only (Münzer et al. 2010). In females and older men (over 60), the IGF-1 
concentrations did not increase during the eight months of CPAP treatment. In our
study, the median age was 54 years, and it included more females than most studies
have, a factor that could help explain why the IGF-1 concentrations remained
unchanged.
6.5 Medication use in comorbidities
Current knowledge on the effect of CPAP therapy on medicine use is controversial.
Previously, the use of medication has been mainly studied as all-cause expenses, not
as the actual use of medicines, let alone according to specific subcategories or 
diseases, or the effects of SDB type. Morbidity and mortality have been more 
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Discussion
thoroughly studied, and it is thought that patients with OSAS have higher direct and
indirect health costs than the controls. This aspect was shown in one study, where
the effect was visible several years before the diagnosis and surprisingly, the effect
extended even to their spouses (Jennum et al. 2014). CPAP therapy seems to
decrease mortality in middle-age and old males, but it appears to have no effect on
women (Jennum et al. 2015).
In our study III, female CPAP users had more illnesses than controls three years
before CPAP initiation, which is in line with the previous data (Bonsignore et al.
2019a). The higher comorbidity noted already at baseline could explain why in our
cohort, the total use of medication was higher in the CPAP therapy group at both 
time points, three years before and three years after CPAP introduction, when 
compared to the control group. Currently, only one registry study has evaluated the
expenses of medication before and after CPAP treatment. The conclusion was that
during an eight-year follow-up, the medication costs did not change in patients on
CPAP therapy, but did increase in untreated group (Jennum & Kjellberg 2011). In 
our study, the increase in medication use was similar in both groups, regardless of
CPAP use. Similar results were found in a Danish study, in which medication use
was increased in patients with OSAS and correspondingly in the controls (Jennum 
et al. 2014).
In our female cohort, when different medication groups were analysed
separately, the increase in medication use for obstructive respiratory diseases and
severe mental illnesses was higher in the CPAP group when compared to the
controls. These results went against our hypothesis that stated that CPAP therapy
could be linked to reduced medication use. Moreover, in our study, the type of SDB
did not have any influence on medication use, as the use was similar in patients with
OSA and UAO. To our knowledge, the effect of the type of SDB on medicine use
has not been studied previously. This aspect emphasises our earlier results and
indicates that comorbidities are linked equally to both conditions, and accentuates
that UAO is not a mild form of SDB (Anttalainen et al. 2010b).
To determine the validity of our control group; the data were compared to the
entire Finnish female population. The medication use in all subcategories increased
from year 1993 to 2001 in Finnish females. However, there was a trend of a slight
decrease in medication when the first two years of follow-up were excluded, the 
years from 1995 to 2001 and in the same categories as found in the controls. 
Therefore, it can be stated here that our control group does represent the Finnish
female population sufficiently, apart from severe mental illnesses, where for some
reason, medication decreased among our controls.
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Cardiovascular medication
Hypertension has had the most attention paid to it as a cardiovascular comorbidity
of SDB (Bonsignore et al. 2019a). However, it has also been suggested that the effect
of CPAP on blood pressure values is not as dramatic as previously thought. In one
meta-analysis, the effect was small but significant, and in addition, the reduction was
dependent on the OSAS severity, compliance, and blood pressure values before
CPAP therapy was initiated (Haentjens et al. 2007). Since the effect of CPAP appears
to be modest, currently it is advised to continue sufficient medication for blood 
pressure even if CPAP therapy is commenced. In our study, patients with SDB
received more medications for hypertension than did controls. That disparity
remained throughout the entire follow-up period. Therefore, our study reinforces the
previous findings, that the medication use did not reduce with CPAP therapy.
In our clinical cohort of women, medicine use for arteriosclerosis and cardiac
arrhythmias decreased in both the controls and the patients using CPAP therapy. The
same phenomenon was observed in the entire Finnish female population. In previous
studies the risk of cardiovascular disease events was suspected to be reduced with
CPAP therapy (Myllylä et al. 2019), but the results were inconsistent. In one study,
the adherence to CPAP > 4 h/night had to be achieved for any protective value
(McEvoy et al. 2016). In our cohort, the decrease in use of these medications could 
be a result of changes in the Finnish guidelines for treatment of cardiovascular
diseases. 
The most common arrhythmia needing medical treatment is arterial fibrillation.
When a patient is diagnosed with AF, anticoagulation therapy is initiated, and 
usually it must be continued for the rest of that patient’s life. Currently, CPAP
therapy is thought to have a protective effect on recurrent AF (Deng et al. 2018), but
there are no studies that suggest a discontinuation of anticoagulant even if CPAP
therapy is commenced. Therefore, the medication use does not change. The 
medication use for symptoms, e.g., beta blockers for tachycardia, could decrease due
to AF treatment, or SDB treatment, resulting in a decrease in medication use.
Metabolic medication
The effect of CPAP therapy on blood glucose has had laborious investigation. SDB
has been associated as being an independent factor for disturbed glucose metabolism
in multiple studies (Anothaisintawee et al. 2016; Kent et al. 2013), and hence it is 
thought to be a risk factor for type 2 diabetes. However, currently it seems that
glycemic control does not improve with CPAP therapy (Labarca et al. 2018; Zhu et
al. 2018), although there are indications that sufficient CPAP adherence (over four
hours per night) may have a protective impact on patients who have both 
cardiovascular complications and diabetes (McEvoy et al. 2016). Our study is in line
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Discussion
with these findings, as the medicine use for diabetes increased similarly in both 
groups, and CPAP did not have a protective effect. Therefore, we concur with the
previous studies that it is essential to continue diabetes medication appropriately in 
OSAS patients, regardless of CPAP therapy initiation.
Respiratory medication
The use of medicines for asthma and/or COPD was increased in our CPAP group 
during the follow-up, unlike for the controls. In one previous study, a European
cohort of SDB patients had a higher prevalence of asthma in females with obesity
(Bonsignore et al. 2018), which was correspondingly reflected in our study
population. Asthma and OSAS are thought to have a causative link (Kong et al.
2017) and there are studies both in favour (Julien et al. 2009) and against (Tveit et
al. 2018) the relationship with asthma and the severity of OSAS. Referral policies
for asthma patients to sleep studies can vary, and have thought to be linked with
different results for various studies (Bonsignore et al., 2019a). This could also be the 
case in our study. Asthma patients have nocturnal symptoms similar to SDB;
therefore, asthmatics can be overrepresented in the CPAP population, resulting in
increased medication use. Moreover, the sleep study was conducted in a pulmonary 
clinic, where respiratory physicians tend to commence more vigorous treatment of
respiratory diseases and that could result in higher medication consumption.
Our study supports the previous knowledge about asthma and COPD prevalence
among females with obesity and OSAS. COPD is long known to coincide with
OSAS (Flenley 1985), and CPAP therapy appears to reduce the risk of death and
hospitalisation of patients with both COPD and SDB (Marin et al. 2010).To our
knowledge, there are no previous studies on SDB and COPD overlap, and the effects
of CPAP on medication. Our finding suggests that medication use for COPD is not 
decreased with CPAP therapy. One reason could be that COPD is a progressive
disease with no curative medication, leading to increased use of medications even
when the OSAS is treated sufficiently. 
Psychiatric medication
In our female study cohort, there was a significant difference in the psychiatric
medicines used between the study groups. The medication group of psychiatric
medicines consisted of merely those medications used for severe mental illnesses,
excluding e.g., mild depression and anxiety. In the CPAP user group, as well as in
the Finnish female population, the use of these medications increased slightly during 
the follow-up time, whereas in our control group that use decreased. This finding
could indicate that the controls who had similar symptoms suggesting SDB at the
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beginning, possibly had another underlying condition, that manifested with similar
symptoms. These conditions could have been diagnosed and probably treated during
the follow-up, thereby resulting in decrease in medication use.
Symptoms of SDB come in broad variations and can bear a resemblance to those
for mental disorders. SDB is estimated to be present in 15-48% of patients with 
schizophrenia (Kalucy et al. 2013), 21-47.5 % of patients with bipolar disorder
(Kelly et al. 2013) and 11-18 % of patients with recurrent depressive disorder
(Ohayon 2003). Moreover, some medications used for severe mental disorders can
aggravate the symptoms of SDB, mainly via weight gain (Szaulińska et al. 2015). 
However, in one review, the prevalence of OSAS was not elevated in those patients
with schizophrenia, bipolar disorder, or severe depression (Gupta & Simpson 2015). 
6.6 The effect of sleep study
In Studies I and II, the sleep study was conducted with PG, which is a standard
method for SDB diagnosis in Nordic countries. As mentioned before, PG focuses on 
respiratory events and cardiac reactions, and sleep stages are not visible, as EEG and 
EOG electrodes are not utilised. However, in the basic diagnostics of OSA or UAO,
PG is sufficient. Therefore, our sleep studies undertaken in pulmonary wards were
reliable and the diagnosis of SDB well assured. If the diagnosis was made with PSG,
the REM-related OSA could have been detected with more certainty, since in PG,
AHI dilutes when the wake time is included in the analysis, and the diagnosis can
thus more possibly be left undiscovered. PG has been criticised for underestimating
SDB, and being insufficient to rule out OSA when the respiratory events are mainly
associated with arousals (Nerfeldt et al. 2014). Therefore, it is now suggested that
PG scoring should have its own diagnostic guidelines (Escourrou et al. 2015).
A static-charge-sensitive bed was widely used in our clinical practise in the last
decades of 20th century but has now been replaced with PG. After the time our study
was performed, there has been discussion about the right categorisation of SCSB
breathing patterns. However, in our study, the classification of obstructive breathing 
included the categories P2 and P3, which are considered as obstructive also today.
SCSB has its advantages. For example, there are no electrodes or probes disturbing
the sleep, making it ideal to evaluate sleep in infants or small children. Moreover,
the traditional measurements of AHI with PG are unable to identify prolonged upper
airway resistance from pure OSA as reliably as when examined with SCSB. Recent
studies have also shown that AHI poorly correlates with cardiovascular comorbidity,
suggesting that other parameters beyond AHI are needed to identify patients who 
will adhere and benefit from CPAP treatment (Saaresranta et al 2016; Zinchuk et al.
2019).
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Discussion
6.7 Strengths and limitations
In Study I and II, we had a medium sized and gender-balanced study population, and 
in Study III, we had only women. Previous studies have been undertaken mainly on
men, and the effects of CPAP therapy cannot, therefore, be evaluated with certainty
in women. Recent studies point toward the realisation that SDB in men and women
are different, and the comorbidities and risks do vary between the genders. Our study 
provides more information on this gap, thereby making treatment of female SDB 
more efficient.
Weight change was evaluated with the help of BMI. It is an international and
standardised method for weight assessment, but it has its limitations. Currently we
know that waist hip ratio is more accurate in evaluating obesity, as BMI does not
take e.g. muscles into account and can overestimate obesity, especially in men.
Moreover, the health consequences of visceral adipose tissue are well known, and if
the patient is not obese by BMI, but has visceral obesity, the risk for comorbidities
is higher.
In Study I, we had substantial number of questionnaires to evaluate different
aspects of patients’ lives. We introduced the questionnaires in the evening, right after
a full meal. This impacts on mood and cravings and the results might be different if
the questionnaires were completed in the morning. Additionally, we did not use food 
diaries, which could have provided a deeper insight in the issues related to weight
gain. Questionnaires administered at a single point at the baseline and follow-up
could just reflect the feelings at the moment of filling out the questionnaire, even if
the instructions referred to a longer time period. The questionnaires used were
standardised and in wide clinical use, making our results reliable. Finally, a large set
of data has its disadvantages. Methodologically, there can be associations based on
the large number of variables that cannot be reproduced in different settings, and
multiple statistical analyses can create incorrect associations. However, our results
were critically administered, and the justification for all the variables and results
were fully considered.
In Study II, there were only single measurements of leptin concentrations in two
time points, although leptin is known to have a circadian rhythm. However, leptin
concentrations were measured approximately at the same time of the day, both at
baseline and at follow-up. In addition, we did not measure leptin concentrations 
shortly after the CPAP therapy was commenced. Therefore, we cannot know with
certainty whether the leptin concentrations had increased already in the initiation
phase of CPAP therapy, or if the concentrations increased later during the treatment.
However, this does not compromise our finding that leptin concentrations 
undeniably increase among females after three years of CPAP use.
In Study III, our results can only be applied to women. Our study population was
moderate in size, so therefore we must be cautious in drawing conclusions from the
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study results regarding the subgroups of medication. Our study data are older in
origin, but the basic guidelines for the treatments of illnesses that we evaluated have
remained similar. The actual drugs can be different or have evolved, but the effect
of CPAP therapy upon use can be evaluated from the data gathered even though that
data are older. We compared the same patients, and we had a control group;
therefore, the effects can be considered reliable. In addition, we controlled for the
CPAP use.
6.8 Clinical implications and future considerations
In the future, the treatment of SDB is going to change and we need more information
on the long-term effects of CPAP therapy, in order to provide the most tailored and
cost-effective treatment. In our study, we have shown, that regardless of the efficient
treatment of SDB and its symptoms, we have not been able to influence weight or
lifestyle, both of which are the essence of our crusade to cure SDB permanently.
Therefore, we suggest that in addition to CPAP therapy, lifestyle counselling should
be provided to patients with SDB, a choice that rarely is the case currently. However,
we have also proved that CPAP alleviates SDB symptoms efficiently, and in the
treatment of resistant depression or anxiety, SDB should be considered and sleep
study duly allocated whenever there are any suspicions of underlying SDB.
Leptin is of particular interest currently, as it is a promising candidate for the
medical treatment of SDB. In mice, intranasal leptin has been proven to alleviate or
even cure OSA (Berger et al. 2019), but the effects in humans are still unknown. 
However, our finding of gender-related reactions to CPAP therapy induced leptin
concentrations could play a useful role in future treatments and should be considered
in the development of the new drug.
The cost-effectiveness of CPAP therapy is something we also need to consider
in the future. The rising number of patients can lead to rising costs for CPAP use,
but if the treatment has a reductive effect on overall costs, CPAP therapy should be
commenced earlier and SDB thereby treated more efficiently. The morbidity in our
study was higher in SDB patients three years before CPAP initiation, and this finding
is in line with earlier studies. In addition, patients with UAO had the same risk profile
and morbidity as patients with OSA, indicating that perhaps these patients should
also be treated more efficiently and much earlier than we currently do. Medication
use remained the same despite the CPAP therapy, but it did not increase more than
what was delivered to the controls, thus indicating that the increase in medication
use might also be reduced.
More research is needed into all these aspects, as multiple and different variables
must be taken into account in these exciting years, as the treatment protocol of SDB 
moves through further change. 
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7 CONCLUSIONS
The main results, according to the aims of the study were as follows:
1. Long-term CPAP therapy does not lead to weight reduction, more active
lifestyle, or more healthy choices of food. However, it does alleviate 
efficiently sleepiness, depressive symptoms, and anxiety and improves
sleep quality.
2. Leptin concentrations increase in females within time, but the increase is
higher if a patient is using long-term CPAP therapy for OSA. In men,
leptin concentrations decrease, but the reduction is lesser when using
long-term CPAP therapy. Long-term CPAP therapy does not influence on
IGF-1 concentrations. No reduction in weight was detected with long-
term CPAP treatment.
3. Medication use for comorbidities does not decrease in women using long-
term CPAP therapy for SDB. However, the increase in medication use 
might be reduced to the same level as in controls. The type of SDB, OSA
or UAO, does not influence on medication use.
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APPENDICES
Appendix 1.
EPWORTH SLEEPINESS SCALE (ESS)
The following questionnaire will help you measure your general level of daytime sleepiness.
You are to rate the chance that you would doze off or fall asleep during different routine 
daytime situations. Answers to the questions are rated on a reliable scale called the Epworth 
Sleepiness Scale (ESS). Each item is rated from 0 to 3, with 0 meaning you would never
doze or fall asleep in a given situation, and 3 meaning there is a very high chance that you
would doze or fall asleep in that situation.
How likely are you to doze off or fall asleep in the following situations, in contrast to just
feeling tired? Even if you haven’t done some of the activities recently, think about how they
would have affected you.
Use this scale to choose the most appropriate number for each situation:
0 = would never doze 2 = moderate chance of dozing 
1 = slight chance of dozing  3 = high chance of dozing 
It is important that you circle a number (0 to 3) for EACH situation.
SITUATION CHANCE OF DOZING
Sitting and reading  0 1 2 3 
Watching television 0 1 2 3 
Sitting inactive in a public place (theater/meeting) 0 1 2 3 
As a passenger in a car for an hour without a break 0 1 2 3 
Lying down to rest in the afternoon 0 1 2 3 
Sitting and talking to someone 0 1 2 3 
Sitting quietly after lunch (with no alcohol) 0 1 2 3 
In a car, while stopped in traffic 0 1 2 3 
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Appendix 2.
DEPS. 
Below there are some statements and questions, which we hope that you will answer by circling the alternative 
which best corresponds with your condition during the last month.
During the last month Never To some extent Relatively Very much
much
I suffered from insomnia 0 1 2 3
I felt sorrowful 0 1 2 3
It felt that everything required exertion 0 1 2 3
I felt listless 0 1 2 3
I felt lonely 0 1 2 3
The future felt hopeless 0 1 2 3
I did not enjoy my life 0 1 2 3
I felt worthless 0 1 2 3
I felt that all joy had left life 0 1 2 3
I felt that my depression did not even ease with 0 1 2 3
the help of family or friends
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SLEEP QUALITY INDEX (PSQI) 
INSTRUCTIONS: The following questions relate to your usual sleep habits during the past month only. 
Your answers should indicate the most accurate reply for the majority of days and 
nights in the past month. Please answer all questions. 
1. During the past month, when have you usually gone to bed at night? 
USUAL BEDTIME _________________________ _ 
2. During the past month, how long (in minutes) has it usually take you to fall asleep each night? 
NUMBER OF MINUTES ______________________ _ 
3. During the past month, when have you usually gotten up in the morning? 
USUAL GETTING UP TIME _____________________ _ 
4. During the past month, how many hours of actual sleep did you get at night? (This may be different than the 
number of hours you spend in bed.) 
HOURS OF SLEEP PER NIGHT _____________ _______ _ 
INSTRUCTIONS: For each of the remaining questions, check the one best response. 
Please answer all questions. 
5. During the past month, how often have you had trouble sleeping because you ... 
Not during the Less than Once or 
past month once a week twice a week 
(a) ... cannot get to sleep within 30 minutes 
(b) ... wake up in the middle of the night or 
early morning 
(c) ... have to get up to use the bathroom 
(d ... cannot breathe comfortably 
(e) ... cough or snore loudly 
(I) ... feel too cold 
(g) ... feel too hot 
(h) ... had bad dreams 
(i) ... have pain 
0) Other reason(s), please describe 
How often during the past month have 
you had trouble sleeping because of this? 
PSQIPIII 1 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
□ □ □ 
Three or more 
times a week 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
Appendices
Appendix 3.
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good Fair1ygood Fairly bad very bad 
6. During the past month, how would you 
rate your sleep quality overall? □ □ □ □ 
Not during the Less than Once or Three or more 
past month once a week twice a week times a week 
7. During the past month, how often have 
you taken medicine (prescribed or 
□ □ □ □ ' over the counter") to help you sleep? 
8. During the past month, how often have 
you had trouble staying awake while driving, 
□ □ □ □ eating meals, or engaging in social activity? 
No problem Only a very Somewhat of Avery 
at all slight problem a problem big problem 
9. During the past month, how much of a 
problem has it been for you to keep up 
□ □ □ □ enough enthusiasm to get things done? 
No bed Partner/ Partner in same 
partner or roommate in room, but not Partner in 
roommate other room same bed same bed 
10. During the past month, how much of a 
problem has it been for you to keep up 
□ □ D □ enough enthusiasm to get things done? 
If you have a roommate or bed partner, ask him/her how often in the past month you have had ... 
Not during the Less than Once or Three or more 
past month once a week twice a week times a week 
(a) .. .loud snoring □ □ □ □ 
(b) .. .long pauses between breaths while asleep □ □ □ □ 
(c) ... legs twitching or jerking while you sleep □ □ □ □ 
(d) ... episodes of disorientation or confusion 
□ □ □ □ during sleep 
(e) Other restlessness while you sleep; 
□ □ □ □ please describe 
PSQ/Pa1112 
Miia Aro
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Appendix 4.
State Trait Anxiety Inventory
Read each statement and select the appropriate response to indicate how you feel
right now, that is, at this very moment. There are no right or wrong answers. Do not
spend too much time on any one statement but give the answer which seems to
describe your present feelings best.
1 2 3 4
Not at all A little Somewhat Very much so
1. I feel calm 1 2 3 4
2. I feel secure 1 2 3 4
3. I feel tense 1 2 3 4
4. I feel strained 1 2 3 4
5. I feel at ease 1 2 3 4
6. I feel upset 1 2 3 4
7. I am presently worrying over possible misfortunes 1 2 3 4
8. I feel satisfied 1 2 3 4
9. I feel frightened 1 2 3 4
10. I feel uncomfortable 1 2 3 4
11. I feel self-confident 1 2 3 4
12. I feel nervous 1 2 3 4
13. I feel jittery 1 2 3 4
14. I feel indecisive 1 2 3 4
15. I am relaxed 1 2 3 4
16 I feel content 1 2 3 4
17. I am worried 1 2 3 4
18. I feel confused 1 2 3 4
19. I feel steady 1 2 3 4
20. I feel pleasant 1 2 3 4
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Appendix 5.
SCALE FOR APPETITE
Please, answer the following questions according to how you feel RIGHT NOW. Please, answer how you
actually feel, REGARDLESS OF CALORIES, FAT, OR, ”HEALTHY FOOD”. How much would you 
ENJOY eating the following 7 different categories of food?
SWEET FOOD such as cakes, sweets, cookies, ice cream, sweet pies
Not at all ________________________________________ Very much
SALTY FOOD such as chips, salty nuts, salty cucumber
Not at all ________________________________________ Very much
FOOD WITH STARCH such as bread, pasta, cereals, potatoes
Not at all ________________________________________ Very much
FRUIT AND JUICE
Not at all ________________________________________ Very much
VEGETABLES
Not at all ________________________________________ Very much
MEAT, CHICKEN, FISH, EGGS
Not at all ________________________________________ Very much
DAIRY PRODUCTS such as milk, cheese, or yoghurt
Not at all ________________________________________ Very much
SCALE FOR HUNGER
How hungry do you feel right now?
Not at all ________________________________________ Very Hungry
hungry
How thirsty do you feel right now?
Not at all ________________________________________ Very Thirsty
thirsty
How full do you feel your stomach is right now?
Not at all ________________________________________ Very full
full
How strong desire do you have to eat right now?
No desire to ________________________________________ Very strong desire
eat at all
How much do you think you could eat right now?
Not at all ________________________________________ Very much
much
102
 
 
 
 
 
  
   
   
  
  
  
  
  
 
 
       
   
   
   
  
 
     
   
   
     
   
   
   
  
    
 
    
 
 
 
 
--------------------------------------------------------------------------------------------
Appendices
Appendix 6.
1. How often do you exercise? (choose one option)
1. not at all
2. less than once a week
3. once a week
4. 2 times a week
5. 3 times a week
6. 4 times a week
7. 5 times a week
2. What is the duration of your one exersice? (choose one option)
1. 0 - 20 minutes
2. 20 - 40 minutes
3. 40 - 60 minutes
4. yli 60 minutes
1. Have you ever smoked? (at least for 6 months straight)
1. yes
2. no
2. Alcohol use for the last six months:
1. Not at all
2. 0-6 bottles of beer per week or corresponding amount of any other alcohol
3. 7-14 bottles of beer, 1-2 bottles of wine, ½-1 bottles spirits or corresponding amount of
any other alcohol in a week
4. 15-24 bottles of beer, 2-4 bottles of wine, or 1-2 bottles of spirits in a week.
Do you have any medication? Please write ALL the medications you use.
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